Open Access Full Text Article

ORIGINAL RESEARCH

FH535 inhibited metastasis and growth of pancreatic cancer cells

Meng-Yao Wu^{1,*} Rong-Rui Liang^{1,*} Kai Chen¹ Meng Shen¹ Ya-Li Tian^{1,2} Dao-Ming Li¹ Wei-Ming Duan¹ Qi Gui¹ Fei-Ran Gong³ Lian Lian^{1,2} Wei Li^{1,6} Min Tao^{1,4-6}

¹Department of Oncology, The First Affiliated Hospital of Soochow University, ²Department of Oncology, Suzhou Xiangcheng People's Hospital, ³Department of Hematology, The First Affiliated Hospital of Soochow University, ⁴Jiangsu Institute of Clinical Immunology, The First Affiliated Hospital of Soochow University, ⁵Institute of Medical Biotechnology, Soochow University, Suzhou, ⁶PREMED Key Laboratory for Precision Medicine, Soochow University, Suzhou, People's Republic of China

*These authors contributed equally to this work

Correspondence: Wei Li; Min Tao Department of Oncology, The First Affiliated Hospital of Soochow University, Suzhou 215006, People's Republic of China Tel +86 6778 0315; +86 6778 0310 Fax +86 512 623 8798 Email liwei10@suda.edu.cn; mtao@medmail.com.cn **Abstract:** FH535 is a small-molecule inhibitor of the Wnt/ β -catenin signaling pathway, which a substantial body of evidence has proven is activated in various cancers, including pancreatic cancer. Activation of the Wnt/ β -catenin pathway plays an important role in tumor progression and metastasis. We investigated the inhibitory effect of FH535 on the metastasis and growth of pancreatic cancer cells. Western blotting and luciferase reporter gene assay indicated that FH535 markedly inhibited Wnt/ β -catenin pathway viability in pancreatic cancer cells. In vitro wound healing, invasion, and adhesion assays revealed that FH535 significantly inhibited pancreatic cancer cell metastasis. We also observed the inhibitory effect of FH535 on pancreatic cancer cell growth via the tetrazolium and plate clone formation assays. Microarray analyses suggested that changes in the expression of multiple genes could be involved in the anti-cancer effect of FH535 on pancreatic cancer cells. Our results indicate for the first time that FH535 inhibits pancreatic cancer cell metastasis and growth, providing new insight into therapy of pancreatic cancer.

Keywords: pancreatic cancer, FH535, β -catenin, metastasis, growth

Introduction

Pancreatic cancer is one of the most aggressive human malignancies worldwide. Despite improvements in surgical and chemotherapeutic approaches over the past decades, the prognosis of pancreatic cancer remains dismal; the average overall 5-year survival rate is <5%.¹ The reasons for this are the challenges associated with diagnosis, which tends to be late and uncertain; more importantly, therapeutic options are limited. Even with early diagnosis and surgical resection with curative intention, nearly all patients develop local recurrence or distant metastases following surgery and eventually succumb to the debilitating effects of metastatic growth.^{2,3} Conventional chemotherapy is rarely curative for metastatic pancreatic cancer. In recent years, there have been important advances in the organization of care for patients with pancreatic cancer; these advances have also resulted in more focused studies on surgical, oncological, and immunological treatment.

The Wnt/ β -catenin pathway is a genetically conserved signaling pathway associated with a variety of human conditions such as birth defects and tumors. Abnormal Wnt/ β -catenin pathway activation is closely related to the development of many cancers.^{4,5} An increasing amount of evidence demonstrates that both the β -catenin-dependent (canonical) and β -catenin-independent (non-canonical) Wnt signaling pathways play a key role in regulating pathological processes by facilitating tumor growth, migration, and invasion. In canonical Wnt signaling, glycogen synthase kinase-3 β (GSK-3 β) phosphorylates β -catenin at certain key residues, leading to its ubiquitination and subsequent degradation.^{5,6} Non-phosphorylated β -catenin accumulates in the cytoplasm,

OncoTargets and Therapy 2015:8 1651-1670

OncoTargets and Therapy downloaded from https://www.dovepress.com/ For personal use only.

submit your manuscript | www.dovepress.com

http://dx.doi.org/10.2147/OTT.\$82718

© 2015 Wu et al. This work is published by Dove Medical Press Limited, and licensed under Grative Commons Attribution — Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions by ond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php and pathway activation leads to nuclear accumulation of β -catenin and interaction with T-cell factor (TCF) transcription factors, subsequently stimulating the downstream target genes, which include the genes participating in cell metastasis and proliferation.^{7,8}

Abnormal Wnt/ β -catenin pathway activation plays an important role in human pancreatic cancer, where it causes extracellular matrix degradation and uncontrolled cell proliferation and differentiation.⁹ Recent studies have demonstrated that FH535 is a synthetic inhibitor of the canonical Wnt signaling pathway; it inhibits the growth of colon, lung, breast, and hepatocellular carcinoma lines,^{10,11} suggesting that small-molecule targeting of the Wnt/ β -catenin pathway could be a promising therapeutic approach for cancers in which this pathway is activated.

In this study, we investigated the anti-cancer effect of FH535 on pancreatic cancer and explored the mechanisms underlying the effect, providing a rationale for further development of FH535 as a promising therapeutic agent for treating pancreatic cancer.

Materials and methods Cell cultures and reagents

The human pancreatic cancer cell lines PANC-1 and BxPC-3 were purchased from American Type Culture Collection (ATCC) (Manassas, VA, USA). The cells were maintained in Dulbecco's Modified Eagle's Medium (DMEM; Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% fetal calf serum (FCS), 100 U/mL penicillin, and 100 μ g/mL streptomycin (Thermo Fisher Scientific) at 37°C in a 5% CO₂ incubator under a humidified atmosphere; the cells were passaged every 2–3 days for exponential growth. FH535 was purchased from EMD Millipore (Billerica, MA, USA).

Western blotting

Total protein was extracted using a lysis buffer (50 mM Tris-HCl [pH 7.4], 150 mM NaCl, 1% Triton X-100, 0.1% sodium dodecyl sulfate [SDS], 1 mM EDTA) supplemented with a protease inhibitor cocktail kit and a phosphatase inhibitor cocktail kit (Hoffman-La Roche Ltd., Basel, Switzerland). The protein extracts were loaded, size-fractionated by SDSpolyacrylamide gel electrophoresis, and transferred to polyvinylidene difluoride membranes (Bio-Rad Laboratories Inc., Hercules, CA, USA). After blocking, the membranes were incubated with the primary antibodies mouse anti- β -catenin (Santa Cruz Biotechnology Inc., Dallas, TX, USA) and rabbit anti- β -actin (Proteintech Group Inc., Chicago, IL, USA) at 4°C overnight. Protein expression was determined using horseradish peroxidase-conjugated anti-mouse or anti-rabbit secondary antibodies, followed by detection using enhanced chemiluminescence (EMD Millipore). Band intensity was visualized using a JS-1035 image analysis scanning system (Shanghai Peiqing Science & Technology, Co., Ltd., Shanghai, People's Republic of China).

Luciferase reporter assay

β-catenin is a dominant factor in the Wnt/β-catenin/TCF signaling pathway, which regulates gene transcription by binding β -catenin and TCF. The activity of this final step in the pathway can be precisely measured using a luciferase reporter construct. The reporter plasmid pTOPFLASH (TCF reporter plasmid; EMD Millipore) contains two sets (the second set is in the reverse orientation) of three copies of the TCF binding site (wild-type) upstream of the thymidine kinase minimal promoter and luciferase open reading frame. The internal control plasmid pRL-SV40 (Promega Corporation, Fitchburg, WI, USA) contains the Renilla luciferase gene. Cells were transiently cotransfected with pTOPFLASH plasmid (500 ng/well) and pRL-SV40 plasmid (100 ng/well) for 6 hours using Lipofectamine 2000 (Thermo Fisher Scientific) according to the manufacturer's protocol. Then, the medium was renewed and FH535 was added. After 24 hours of treatment, cell lysates were subjected to the dual luciferase reporter assay according to the manufacturer's recommendations; luciferase activity was measured using a luminometer (Turner Designs, Sunnyvale, CA, USA). The results are expressed as relative luciferase activity, ie, the ratio of firefly luciferase activity over Renilla luciferase activity.

Wound healing assay

Cells (1×10⁴/well) were seeded in 96-well plates and grown to confluence. The monolayer culture was artificially scrape wounded with a sterile micropipette tip to create a denuded zone of constant width. Each well was washed with phosphate-buffered saline twice to remove the detached cells before FH535 treatment. Cell migration to the wounded region was observed using an XDS-1B inverted microscope (MIC Optical and Electrical Instrument, Chongqing, People's Republic of China) and photographed (×40 magnification). Images were captured at 0, 8, and 12 hours to monitor the wound healing process. The wound areas were measured using ImageJ (NIH, Bethesda, MA, USA).

Transwell invasion assay

We used a 24-well Transwell plate with an 8 μ m pore size polycarbonate filter membrane (Corning Incorporated, Corning, NY, USA). Cells (1×10⁵) in 100 μ L serum-free DMEM were added to the Matrigel-coated top chamber (BD Biosciences, San Jose, CA, USA); the bottom chamber contained DMEM with 10% FCS. The cells were incubated for 24 hours; cells that had invaded through the Matrigel-coated membrane were fixed and stained with crystal violet and counted under a light microscope in five random fields in a blinded fashion.

Adhesion assay

Cells were resuspended in complete medium and seeded in 24-well plates at 1×10^4 cells/mL. After 5-hour incubation, the unattached cells were removed to another well. The attached and unattached cells were evaluated using the 3-[4,5-dimethylthiazol-2-yl] 2,5-diphenyltetrazolium bromide (MTT) assay. The adhesion rate was calculated as follows: (absorbance of attached cells/[absorbance of attached cells + absorbance of unattached cells]) $\times100\%$.

MTT assay

Cell growth was evaluated using the MTT assay. Cells (5×10⁴/ well) were seeded in 24-well tissue culture plates. Blank control was treated with DMSO. After FH535 treatment, MTT (Sigma-Aldrich Co., St Louis, MO, USA) was added to each well (final concentration, 0.5 mg/mL), followed by 4-hour incubation at 37°C. The medium was removed, and 800 μ L of dimethyl sulfoxide was added to each well. The absorbance of the mixture was measured at 490 nm using a microplate enzyme-linked immunosorbent assay reader (Bio-Rad Laboratories Inc.). The relative cell viability was calculated as follows: relative cell viability = (mean experimental absorbance/mean control absorbance) ×100%.

Plate clone formation assay

Cells (200/well) were seeded in 24-well plates and treated after 12 hours. After 15 days, the cells were stained with 1% methylrosanilinium chloride, and the number of visible colonies was counted. The relative clone formation ability was calculated as follows: (mean experimental clone number/ mean control clone number) $\times 100\%$.

Cell cycle analysis

Before treatment, the cells were serum starved for 24 hours to synchronize the cell cycle. Then, FCS was added to the cells, followed by various concentrations of FH535. Following 24 hours of FH535 treatment, the cells were fixed in 80% cooled ethanol and incubated with 0.5% Triton X-100 solution containing 1 mg/mL RNase A at 37°C for 30 minutes. Next, propidium iodide (Sigma-Aldrich Co.) was added to the wells (final concentration, 50 µg/mL), followed by 30-minute incubation in the dark. Cellular DNA content was analyzed using a fluorescence-activated cell sorter (Becton Dickinson, Franklin Lakes, NJ, USA). Data

were processed using ModFit LT software (Verity Software House, Topsham, ME, USA).

Microarray assay

Sample preparation and processing were performed as described in the GeneChip Expression Analysis Manual (Agilent Technologies, Santa Clara, CA, USA). Differentially expressed genes were screened using Agilent 44K human whole-genome oligonucleotide microarrays. The selection criterion was greater than twofold difference in expression (difference in upregulated expression was greater than twofold; difference in downregulated expression was less than 0.5-fold). Hierarchical clustering of samples was performed using an average linkage algorithm using TIGR MultiExperiment Viewer (The Institute for Genomic Research, Rockville, MD, USA).

Statistical analysis

Each experiment was performed in at least triplicate. Results are expressed as the mean \pm standard deviation. Statistical analysis was performed using an unpaired Student's *t*-test. *P*<0.05 was considered significant.

Results

FH535 inhibited the β -catenin pathway in pancreatic cancer cells

Treatment with 20 μ M FH535¹² did not affect nuclear or total β -catenin expression in the BxPC-3 cells, but downregulated nuclear and total β -catenin in the PANC-1 cells (Figure 1A). The luciferase reporter assay confirmed that FH535 suppressed TCF-dependent transcription, which may have led to dysregulation of the genes downstream of the β -catenin pathway (Figure 1B). To verify this, we performed microarray analyses to determine the mRNA expression changes in 138 genes downstream of the β -catenin pathway using Agilent 44K human whole-genome oligonucleotide microarrays (http://www.stanford.edu/group/nusselab/cgi-bin/wnt/target_genes); 20 μ M FH535 upregulated or downregulated multiple genes (Figure 1C, Table 1).

FH535 inhibited pancreatic cancer cell migration

In all, 20 μ M FH535 inhibited pancreatic cancer cell migration in a time-dependent manner (Figure 2A). To investigate the mechanisms involved, we analyzed the microarray data to illustrate the expression of genes participating in focal adhesion (Figure 2B, Table 2),^{13,14} adhesion junctions (Figure 2C, Table 3),^{15–17} tight junctions (Figure 2D, Table 4),^{18–23} and cell motility (Figure 2E, Table 5).^{24–27}

FH535 inhibited pancreatic cancer cell invasion

The Matrigel invasion assay revealed that FH535-treated cells had significantly decreased invasive capacity as compared with the control cells (Figure 3A), supporting the premise that FH535 inhibits pancreatic cancer cell invasion. Moreover, FH535 inhibited the adhesion ability of pancreatic cancer cells dose-dependently (Figure 3C). We also analyzed the microarray data to explore the changes in the expression of genes involved in the in vitro invasion process, including extracellular matrix degradation (Figure 3B, Table 6), cell adhesion (Figure 3D, Table 7),^{28,29} and epithelial–mesenchymal transition (EMT) (Figure 3E, Table 8).^{30–33}

FH535 inhibited pancreatic cancer cell growth

Using MTT assay, we evaluated the inhibitory effect of FH535 on pancreatic cancer cell line growth. The proliferation of PANC-1 and BxPC-3 cells cultured for up to 48 hours with FH535 was significantly inhibited time-dependently and dose-dependently as compared to the control cells (Figure 4A). The clone formation assays confirmed the dose-dependent inhibitory effect of FH535 on pancreatic cancer cell growth (Figure 4B). We performed cell cycle analysis to confirm the antimitogenic effect of FH535. FH535 induced G2/M accumulation and decreased the cell population in the G0/G1 and S phases dose-dependently (Figure 4C). The expression profile of the cell cycle–related genes obtained from microarray analyses was analyzed (Figure 4D, Table 9).³⁴

Discussion

It is widely acknowledged that the prognosis of pancreatic cancer is very poor. The canonical Wnt/ β -catenin signaling pathway plays a key role in tumor development and dissemination. Classical Wnt signaling pathway causes accumulation of β -catenin in cytoplasm in complex with the transcription factor TCF/LEF that regulates target gene expression.^{9,35} Dysregulation of Wnt/ β -catenin signaling and altered transcription of β -catenin/TCF-regulated genes are found in many cancers,³⁶ including pancreatic cancer.³⁷ In this regard, we focused on characterizing the mechanisms of the anti-tumor effect of FH535 on pancreatic cancer cells.

Western blotting revealed that FH535 did not affect β -catenin expression in BxPC-3 cells. Interestingly, FH535




Figure I (Continued)

С

FH535	Gene	•		treatment			
4609 3875	G ^e MYC	& 4609	\downarrow	Gene	ID	Normalized i	ntensity
4609 3875 9232 51129 3887 960	CD44	960	t ↑	Celle		Control	
960 5204 3858	WISP2	8839	Ļ				FH535
900 5204 3858 10744 332 754 754 7423			\downarrow	MYC	4609	16.268158	15.204586
754 7423 3491 51035	FOSL1	8061		KRT18	3875	15.975001	16.022995
51035 3855 8839 6662	SNAI1	6615	\downarrow	PTTGI	9232	15.680945	15.73604
6662 2020 182 8061	KRT73	319101	\downarrow	ANGPTL4 KRT81	51129 3887	15.190848 15.0413	15.278334 14.423697
26292	GJA1	2697	↑	CD44	960	15.006962	16.199093
6615 319101 2697	DKK3	27122	\downarrow	PFDN5	5204	14.879261	14.964103
79191 6899 27122	CCND3	896	\downarrow	KRTIO	3858	14.799751	13.889791
3725 339287 144501	KRT83	3889	\downarrow	PTTG2	10744	14.772796	14.547727
896 1029 1047	CEBPD	1052	\downarrow	BIRC5	332	14.757564	14.219355
26255	EGFR	1956	Ŷ	PTTGIIP	754	14.684395	14.533192
3880 1052 5467	CDX4	1046	\downarrow	VEGFB	7423	14.498004	13.671163
84168 1956 1046	ISLR	3671	Ļ	CYR61	3491	14.279853	14.790296
3671 117581 7422	CTGF	1490	Ť	UBXNI	51035	14.231482	14.049252
1490 8324 3801	KRT85		Ļ	KRT7	3855	14.184294	13.285099
84168 1956 1046 3671 117581 7429 1490 8324 3891 595 7088 1044 3856 8829 22943 3667 4313		3891		WISP2	8839	13.732449	12.493675
1044 3856 8829	TLE1	7088	Ļ	SOX9	6662	13.574989	13.415171
22943 3667 4313	CDX1	1044	\downarrow	EN2	2020	13.393019	12.721889
8517 7074	KRT8	3856	\downarrow	JAGI	182	12.427784	12.687155
8517 7074 1958 4233 632 7424 196 8913 3866 8613 3892 25984	TLAM1	7074	\uparrow	FOSLI	8061	12.344017	11.102832
424 96 913	EGR1	1958	\downarrow	МҮСВР	26292	12.284651	11.974781
6 13	MET	4233	Ŷ	SNALL	6615	12.28132	10.385736
2637	AHR	196	↑	KRT73	319101	12.23975	11.053284
2637 390792 39780 5329 3398 10296	CACNA1G	8913	Ļ	GJA I	2697	12.226766	13.521647
98 296 01	KRT15	3866	Ļ	IRX3	79191	12.224495	12.16053
01 14 81 92	KRT23	25984	¥	TBXI	6899	12.181493	12.043698
3792 5979 30700			↓ ↓	DKK3	27122	12.076692	10.961267
64220 688 3851	KRT39	390792		JUN MSLI	3725 339287	12.038464 11.920114	12.673436
23190 51176 51350 137886	DAB2	1601	1	KRT80	144501	11.87818	11.438548 12.039767
91544 4035	ETS2	2114	↑	CCND3	896	11.576098	12.039787
165324	KRT31	3881	\downarrow	CDKN2A	1029	11.343829	11.097562
3882 2249	RET	5979	\downarrow	EFNBI	1947	11.337793	10.368351
1896 3882 2249 3850 7993 6495	UBXN6	80700	\downarrow	PTTG3P	26255	11.33311	10.750982
8456 2120 3848	STRA6	64220	\downarrow	KRT83	3889	11.319811	9.89329
	UBXN4	23190	\uparrow	KRT19	3880	11.289505	11.101922
3576 4915 860 4320 999 6934 196374 6932 6608 1948 9076 3883 1462 4318 28514	KRT76	51350	\downarrow	CEBPD	1052	11.196305	10.068165
6934 196374 6932	UBXN2B	137886	∙ ↑	PPARD	5467	11.19087	10.731722
6608 1948 9076	LRP1	4035	Ļ	ANTXRI	84168	11.149265	12.122571
3883 1462				EGFR	1956	11.122326	12.333595
28514 3860 3481 353288	KRT9	3857	Ļ	CDX4	1046	10.933424	9.588729
353288 3604	FGF4	2249	Ļ	ISLR	3671	10.854443	9.725897
3604 121391 7291 4897	UBXN8	7993	↑	TWIST2	117581	10.853075	10.129753
7297 4897 2254 4982 10752 3885 3853 1906	RUNX2	860	↑	VEGFA	7422	10.833399	10.087871
3885 3853	TCF7L2	6934	Ŷ	CTGF	1490	10.809845	11.98555
4843 8200	CLDN1	9076	\uparrow	FZD7	8324	10.711324	9.901575
894 8788 8688	SOX2	6657	Ŷ	KRT85	3891	10.621079	9.606193
4843 8200 894 8788 8688 3569 6657 7043 3886 5743 8845	PTGS2	5743	↑	CCNDI	595	10.543621	10.14267
3886 5743	BTRC	8945	, ↓	TLEI	7088	10.343489	9.271956
8940	2	0010		CDXI	1044	10.329419	9.136879
the Wnt/β-	catenin pathway in	pancreatic can	cer cells.	KRT8	3856	10.267347	8.319682

NRPI

DKK I

IRSI

MMP2

IKBKG

TIAM I

Figure 1 FH535 suppressed the Wnt/ β -catenin pathway in pancreatic cancer cells. Notes: (A) Time-dependent decrease by FH535 of nuclear and total β -catenin protein levels in PANC-1 cells; FH535 did not affect nuclear or total $\beta\text{-catenin}$ expression in BxPC-3 cells. (B) Dose-dependent decrease by FH535 of TCFdependent transcription. **P<0.01, significant differences vs the respective control groups. (C) Microarray analysis of expression regulation of genes downstream of the Wnt/ β -catenin pathway upon 20 μ M FH535 treatment. Up and down arrows indicate gene expression significantly upregulated or downregulated, respectively, by twofold. Abbreviations: TCF, T-cell factor; h, hours.

11.627998 (Continued)

9.627893

10.979951

9.412593

9.295626

10.3609915

10.246916

10.211538

10.175792

10.153262

10.132635

10.117085

8829

22943

3667

4313

8517

7074

Table I (Continued)

D	ov	e	or	es	S

Gene	ID	Normalized intensity			
		Control	FH535		
EGRI	1958	10.007974	8.180263		
MET	4233	9.986441	12.74971		
BGLAP	632	9.971276	9.414629		
VEGFC	7424	9.923567	10.21814		
AHR	196	9.886938	11.93648		
CACNAIG	8913	9.812038	8.560494		
KRT15	3866	9.7214575	8.709181		
PPAP2B	8613	9.718731	9.956581		
KRT86	3892	9.707824	9.012362		
KRT23	25984	9.573925	7.977122		
GBX2	2637	9.409858	9.626151		
KRT39	390792	9.284486	7.929165		
WNT3A	89780	9.275467	8.68014		
PLAUR	5329	9.265003	8.37788		
ID2	3398	9.226584	8.999163		
MAEA	10296	9.087043	8.91366		
DAB2	1601	9.034534	10.517419		
ETS2	2114	8.999426	10.44546		
KRT3 I	3881	8.998071	7.96933		
TNFRSFIIA	8792	8.943393	9.029845		
RET	5979	8.9224615	7.809108		
UBXN6	80700	8.850218	7.6966906		
STRA6	64220	8.746183	7.1663184		
KLF5	688	8.6543455	8.714795		
KRT4	3851	8.640165	7.6698284		
UBXN4	23190	8.607909	10.505396		
LEFI	51176	8.601926	9.380911		
KRT76	51350	8.571253	7.397269		
UBXN2B	137886	8.2286415	9.982969		
UBXNII	91544	8.179481	7.272692		
LRP I	4035	8.175423	6.988433		
UBXN2A	165324	8.133479	7.9562063		
KRT9	3857	8.110517	7.0731263		
EDA	1896	8.09645	7.4072337		
KRT32	3882	8.087603	7.7537346		
FGF4	2249	7.9492774	6.5977035		
KRT3	3850	7.8908534	8.469248		
UBXN8	7993	7.86574	9.013798		
SIX I	6495	7.818405	7.9264607		
FOXNI	8456	7.7998743	6.8640747		
ETV6	2120	7.7085342	7.0067773		
KRTI	3848	7.5221066	6.7497764		
IL8	3576	7.501872	6.6113296		
NTRK2	4915	7.497469	7.1365094		
RUNX2	860	7.4688272	8.628798		
MMPTI	4320	7.460847	7.2920337		
CDHI	999	7.3595057	7.319695		
TCF7L2	6934	7.3556123	8.6040535		
KRT78	196374	7.349466	6.8676143		
TCF7	6932	7.270456	7.664296		
SMO	6608	7.222788	7.0400887		
EFNB2	1948	7.1960526	7.26771		
CLDNI	9076	7.1643777	8.943991		
KRT33A	3883	7.121948	6.808277		
VCAN	1462	7.045421	6.763195		
MMP9	4318	7.0101504	6.7540355		
DLLI	28514	6.969655	6.5782347		
KRTI3	3860	6.949356	5.971072		
IGF2	3481	6.933426	6.170534		

Gene	ID	Normalized intensity			
		Control	FH535		
KRT26	353288	6.869997	6.697632		
TNFRSF9	3604	6.862919	6.6031585		
KRT74	121391	6.778076	6.538765		
TWIST I	7291	6.765423	6.105777		
NRCAM	4897	6.677019	6.7818675		
FGF9	2254	6.6647215	5.7855196		
TNFRSFIIB	4982	6.6092443	6.618697		
CHLI	10752	6.6082654	6.3569694		
KRT34	3885	6.601664	6.199431		
KRT6A	3853	6.536037	5.9656916		
EDNI	1906	6.476451	6.7537594		
NOS2	4843	6.425461	6.333558		
GDF5	8200	6.3569694	6.3291264		
CCND2	894	6.3239446	5.996339		
DLKI	8788	6.2332454	6.884508		
KRT37	8688	5.971611	5.881136		
IL6	3569	5.7313643	5.9466343		
SOX2	6657	5.6166873	6.7975965		
TGFB3	7043	5.5891886	6.0552535		
KRT35	3886	5.5883365	6.3580856		
PTGS2	5743	5.5262737	7.601541		
BTRC	8945	5.3152456	7.7473273		

Table I (Continued)

downregulated the protein level of total β -catenin in the PANC-1 cells, which differed from the results of most previous studies.¹⁰ This cell type-dependent downregulation of β -catenin could have been due to the stabilization of axin, which suppresses β -catenin.¹¹ Axin is characterized as a tumor-suppressor gene, and it plays a key role in inhibiting the canonical Wnt pathway by forming molecular complexes with other proteins such as GSK-3ß and adenomatous polyposis coli (APC).³⁸ Whether or not β -catenin expression was inhibited, the luciferase reporter assay proved that transcriptional activity of β -catenin pathway was decreased, which was consistent with previous study findings.10

Metastasis, the leading cause of cancer-related death, is a complex process comprising several steps, all of which we found were affected by FH535. First, FH535 inhibited pancreatic cancer cell migration. Microarray analyses revealed that FH535 altered the expression of several migrationrelated genes, which participate in focal adhesion, adhesion junctions, tight junctions, and/or motility regulation. Among these genes, the focal adhesion-related gene PTEN, considered "the most highly mutated tumor-suppressor gene in the post-p53 era",³⁹ plays a role in controlling cell migration.⁴⁰ The loss of PTEN protein expression or function has been reported in many human cancers, including ovarian, endometrial, and prostate carcinoma; breast cancer; and primary gastrointestinal stromal tumor.41,42 We also found that FH535 downregulated the adhesion junction-related gene TLN1,




Figure 2 (Continued)




Figure 2 FH535 inhibited pancreatic cancer cell migration.

Notes: (A) Time-dependent inhibition by FH535 of PANC-1 and BxPC-3 cell migration. **P<0.01, significant differences vs the respective control groups. Microarray analysis of (B) focal adhesion-related, (C) adhesion junction-related, (D) tight junction-related, and (E) cell motility-related gene expression regulation upon FH535 treatment. Up and down arrows indicate gene expression significantly upregulated or downregulated, respectively, by twofold. Asterisks indicate genes downstream of the Wnt/ β -catenin pathway.

Abbreviation: h, hours.

which encodes a cytoskeletal protein that is concentrated in areas of cell–substratum and cell–cell contact. The encoded protein plays a significant role in actin filament assembly and in the spread and migration of various cell types.^{43,44} TLN1 is codistributed with integrins in the cell surface membrane, aiding the attachment of adherent cells to extracellular matrices and lymphocytes to other cells. In our study, tight junction protein 1 (TJP1), which plays a critical role in cell–cell interaction, proliferation, and differentiation, was upregulated. TJP1 is an important marker of tight junction integrity, which is disrupted in many highly invasive cancers; upregulated TJP1 correlates with favorable survival

Gene	ID	Normalized in	tensity		
Gene		Control	FH535	ITGALI	22801
	2021			ITGA9	3680
RPSA RHOA	3921	16.551584	6.069508 4.78665	PIK3CA	5290
ACTN4	387 81	15.761177 15.032014	14.01403	CRK	1398
CAPN2	81		14.01403	ITGA2B	3674
RACI	5879	14.947017	15.113209	PXN	5829
FLNA		14.251518		SPTB	6710
flna FLNB	2316	14.083586	13.488903	PTEN	5728
flind ITGB5	2317 3693	13.958575 13.888797	3.296808 3.484464	CASK	8573
				ITGA2	3673
DNMI	1759	13.640091	12.518821	SORBSI	10580
TMEM132A	54972	13.622586	13.150153	SELE	6401
RAPIA	5906	13.5597315	14.039375	ARHGAP5	394
HGS	9146	13.533683	13.846248	ITGAI	3672
VCL	7414	13.376745	13.681126	ZEB2	9839
DIAPHI	1729	13.16062	13.659487		
GNGII	2791	13.022779	13.403848		
AKTI	207	12.957863	12.259176		
RAC2	5880	12.955015	11.604415	Table 3 Mi	
ITGA3	3675	12.797894	12.391577		croarray anal
ITGBI	3688	12.738785	13.636554	expression r	egulation upo
CAVI	857	12.61244	13.617725	Gene	ID
ITGB2	3689	12.546266	11.473748		
ACTNI	87	12.409878	11.967234		5217
ITGAV	3685	12.278682	14.3424	PFNI	5216
ITGA6	3655	12.273888	14.392418	RHOA	387
ITGA5	3678	12.169847	10.866323	ACTN4	81
ILK	3611	12.11682	11.583433	CD44	960
TLNI	7094	12.096641	10.645829	RACI	5879
SGCE	8910	12.047686	12.282321	CTNNAI	1495
ITGB4	3691	11.982763	11.56935	FLNA	2316
PRKCA	5578	11.918201	13.803304	MAPREI	22919
	1499	11.900537	11.841962	DIAPHI	1729
FXYD5	53827	11.859393	10.980669	RAC2	5880
AKT2	208	11.791592	10.995004	CD99	4267
CAV2	858	11.534644	11.731664	JUP	3728
VAV2	7410	11.322939	10.17948	ACTNI	87
CDC42	998	11.250544	11.791042	CDH2	1000
PARVB	29780	11.224628	9.830263	TLNI	7094
ZYX	7791	10.997072	9.663998	IQGAPI	8826
VASP	7408	10.877319	10.418066	CTNNBI	1499
RAFI	5894	10.594473	10.865986	РКРЗ	11187
SHCI	6464	10.287678	8.595637	CAV2	858
DSP	1832	10.226259	11.500326	MGAT5	4249
PARVA	55742	10.0804615	10.301352	CSNK2A1	1457
ITGAM	3684	10.003317	8.889115	PLEK2	26499
AKT3	10000	9.999831	12.071189	ANAPCI	64682
HRAS	3265	9.972342	9.272375	NOTCHI	4851
PDPKI	5170	9.005413	9.698432	CDC42	998
HPSE	10855	8.978405	8.067395	NOTCH2	4853
PTK2	5747	8.939062	10.820772	WASL	8976
DNM2	1785	8.613899	7.43392	DLG5	9231
SH3PXD2A	9644	8.566784	9.949804	SRC	6714
BCARI	9564	8.529809	7.7692404	PAK4	10298
ACTN2	88	8.437073	7.474538	VEGFA	7422
PARD6B	84612	8.172608	9.636746	ZEBI	6935
SOSI	6654	7.9648976	7.5355105	JAM3	83700
DST	667	7.7908773	11.245214		5819

Table 2 (Continued)						
Gene	ID	Normalized intensity				
		Control	FH535			
ITGA I I	22801	7.7725782	7.250522			
ITGA9	3680	7.725706	7.2797456			
РІКЗСА	5290	7.546133	9.475706			
CRK	1398	7.5114365	8.404298			
ITGA2B	3674	7.474538	6.8249826			
PXN	5829	7.426979	6.493304			
SPTB	6710	7.143782	6.598218			
PTEN	5728	7.0376005	9.120998			
CASK	8573	6.554297	9.147331			
ITGA2	3673	6.538141	10.171594			
SORBS I	10580	6.5160394	7.080136			
SELE	6401	5.8820415	7.629673			
ARHGAP5	394	5.628543	7.9602804			
ITGAI	3672	5.3547735	7.6031985			
ZEB2	9839	5.2203803	6.942315			

 Table 3 Microarray analysis of adhesion junction-related gene

 expression regulation upon FH535 treatment

725 748	Gene	Gene ID Normaliz		ized intensity		
8 4			Control	FH535		
-	PFNI	5216	16.843973	16.144138		
3	RHOA	387	15.761177	14.786651		
	ACTN4	81	15.032014	14.01403		
	CD44	960	15.006962	16.199093		
329	RACI	5879	14.251518	15.113209		
21	CTNNA I	1495	14.209974	14.654735		
	FLNA	2316	14.083586	13.488903		
	MAPREI	22919	13.413141	13.875792		
2	DIAPHI	1729	13.16062	13.659487		
)	RAC2	5880	12.955015	11.604415		
4	CD99	4267	12.8705635	12.11682		
54	JUP	3728	12.776809	12.098349		
	ACTNI	87	12.409878	11.967234		
2	CDH2	1000	12.27524	13.657263		
3	TLNI	7094	12.096641	10.645829		
	IQGAPI	8826	11.903805	15.008826		
	CTNNBI	1499	11.900537	11.841962		
6	РКРЗ	11187	11.572304	11.483009		
	CAV2	858	11.534644	11.731664		
6	MGAT5	4249	11.399225	12.44798		
2	CSNK2A1	1457	11.389523	10.994029		
	PLEK2	26499	11.380254	12.049034		
9	ANAPCI	64682	11.330902	11.025982		
;	NOTCHI	4851	11.311136	10.345143		
	CDC42	998	11.250544	11.791042		
;	NOTCH2	4853	11.125797	10.202223		
2	WASL	8976	10.930079	12.483249		
	DLG5	9231	10.567565	11.019769		
	SRC	6714	10.48147	9.648777		
)4	PAK4	10298	10.446864	8.676079		
8	VEGFA	7422	10.250756	7.901348		
	ZEBI	6935	10.177025	13.283847		
05	JAM3	83700	10.084784	9.556893		
ł	PVRL2	5819	10.018614	8.147698		

Table 3 (Continued)

Gene	ID	Normalized in	ntensity	Gene	ID	Normalized in	tensity
		Control	FH535			Control	, FH535
MET	4233	9.986441	12.74971	EZR	7430	13.144885	12.5669
CSNK2A2	1459	9.960693	9.169151	JAG I	182	12.427784	12.6871
PTPNI	5770	9.82763	9.271097	ACTNI	87	12.409878	11.9672
РТК2В	2185	9.636893	10.68203	TSPAN I 3	27075	12.246902	11.3793
DOCKI	1793	9.48097	11.021774	ILK	3611	12.11682	11.5834
MAPKI	5594	9.240688	9.218932	ICAM I	3383	12.0056095	11.1184
ARHGEF7	8874	9.037083	9.147919	CLDN7	1366	11.972866	11.0326
CBLLI	79872	9.0251875	9.311203	MMPI	4312	11.905035	12.8874
РКР2	5318	9.022291	10.025781	CTNNBI	1499	11.900537	11.8419
BAIAP2	10458	9.018734	8.004229	COLI 6A I	1307	.64775	10.7777
IAM2	58494	8.789471	8.162707	CSNK2A1	1457	11.389523	10.9940
CAV3 ACTN2	859 88	8.535716 8.437073	8.229119 7.474538	ENAH	55740	11.354481	13.3981
PKPI	5317	8.423988	7.3570046	MLLT4	4301	11.299263	13.2757
CDH3	1001	8.389479	7.50349	CDC42	998	11.250544	11.7910
CSFI	1435	8.360545	7.4550886	IGFIR	3480	11.2369585	12.1404
TJP3	27134	8.295799	7.207067	CLDN I 9	149461	11.222952	10.2780
NASFI	8936	8.178464	7.4462004	CTGF	1490	10.809845	11.9855
PVRLI	5818	8.152037	7.283169	FZD7	8324	10.711324	9.90157
ESRI	2099	8.048168	7.405365	MAPRE2	10982	10.535324	11.3757
OCLN	100506658	8.036663	9.494983	SVIL	6840	10.304885	.463
PIP5KIC	23396	7.9606485	7.254657	CLDN2	9075	10.221999	7.95973
CTNNDI	1500	7.8659673	7.09317	THBS3	7059	10.1687765	9.73656
MAPIB	4131	7.7052383	10.589897	LIMK I	3984	10.151468	9.52237
DSG2	1829	7.513804	8.2605915	MPP5	64398	10.149654	12.0644
CDHI	999	7.3595057	7.319695	TIAM I	7074	10.117085	11.6279
ACTN3	89	7.355976	6.6988516	CGN	57530	10.004088	9.98775
VCAN	1462	7.045421	6.763195	CSNK2A2	1459	9.960693	9.16915
DLLI	28514	6.969655	6.5782347	PRKCI	5584	9.934886	11.6336
VPS I 3A	23230	6.859817	10.562696	CRKL	1399	9.737389	9.57436
DSG4	147409	6.608555	6.1116643	TJAPI	93643	9.66933	9.60907
DSC2	1824	6.3962626	7.24841	CLDN I 2	9069	9.506469	10.8394
NADL	10207	6.08029	8.808925	TJPI	7082	9.28694	12.1348
PNN	5411	5.9342465	7.5790677	PARD6A	50855	9.12321	8.36281
APC	324	5.3153567	6.5241365	ARHGEF7	8874	9.037083	9.14791
TGA2	3673	6.538141	10.171594	PDPKI	5170	9.005413	9.69843
SORBSI	10580	6.5160394	7.080136	CDH5	1003	8.708324	7.58566
SELE	6401 394	5.8820415	7.629673	LMO7	4008	8.558113	9.27710
ARHGAP5		5.628543	7.9602804	SPTANI	6709	8.494044	7.78640
TGA I ZEB2	3672	5.3547735 5.2203803	7.6031985 6.942315	ACTN2	88	8.437073	7.47453
LEDZ	9839	5.2203603	0.742315	CLDN9	9080	8.4181795	7.59402
				CSFI	1435	8.360545	7.45508
Table 4 M	licroarray analysis	of tight junctio	n-related gene	TJP2	9414	8.343918	7.34912
	egulation upon FH	- ·	in related gene	HASI	3036	8.124433	7.65732
expression		555 treatment		CLDN I 6	10686	7.9999046	7.02229
Gene	ID	Normalized in	tensity	AMOTLI	154810	7.8963585	7.81007
		Control	FH535	CRK	1398	7.5114365	8.40429
	207			ACTN3	89	7.355976	6.69885
RHOA CLDN4	387	15.761177	14.786651	PRKCG	5582	7.321149	6.91128
	1364	15.11957	14.539507	CLDN6	9074	7.220466	6.65783
ACTN4	81	15.032014	14.01403	CLDNI	9076	7.1643777	8.94399
CD44	960	15.006962	16.199093	CLDN I 5	24146	7.0927997	6.57952
CAPN2	824	14.947017	15.841314	CLDNIO	9071	7.0557775	6.61346
TIMP2	7077	14.796619	14.858342	PTEN	5728	7.0376005	9.12099
CFLI	1072	14.710272	13.114106	SMAD2	4087	6.9688606	9.49636
CSNK2B	1460	14.4039135	14.575101	PARD3	56288	6.94016	7.33421
RACI	5879	14.251518	15.113209	CLEC3B	7123	6.6491346	6.55877
CTNNA I	1495	14.209974	14.654735	SPP I	6696	6.37645	6.84292
MAPREI	22919	13.413141	13.8757925	MAGH	9223	6.3656254	7.16813
ARHGDIA	396	13.207352	11.634186	CTTN	2017	6.2022476	6.69590
				ERBB3	2065	6.178696	5.99266

Gene

VIM

PERP

MYH9

RHOA

ACTN4

TIMP2

MSN

CFLI

RACI

RAPIB

TIMPI

CDK4

RHOC

LAMCI

ACTR3

DIAPHI

EZR

VAPA

AKTI

RAC2

ACTR2

ITGBI

PRKCZ

ITGB2

ACTNI

SGCE

ICAM I PPL

PRKCA

PPPDE2

ENAH

CDC42

EGFR WASL

CALDI

STEAPI

TGFBI

RDX MCAM

ARF6

SVIL

RGS2

VEGFA

CAPNI

FIIR

RND3

MMP2

WASF2

FATI

RHOB

RASAI

PTK2B

ROCKI

RAPGEFI

CAMK2N1

ILK

VCI

 Table 5 Microarray analysis of cell motility-related gene expression regulation upon FH535 treatment

ID

743 I

4627

387

7077

4478

1072

5879

5908

7076

1019

389

3915

7414

10096

1729

7430

9218

5880

10097

3688

5590

3689

3611

8910

3383

5493

5578

27351

55740

998

1956

8976

800

26872

7040

55450

5962

4162

382

6840

5997

7422

50848

823

390

4313

10163

2195

388

2889

5921

2185

6093

87

207

81

64065

Normalized intensity

FH535

18.417988

17.530819

15.906586

14.786651

14.01403

14.858342

15.357616

13.114106

15.113209

15.037672

13.233850

13.635977

12.094296

14.51922

13.681126

14.45616

13.659487

12.566931

13.857084

12.259176

11.604415

13.651513

13.636554

11.836956

11.473748

11.967234

11.583433

12.282321

11.118488

11.51075

13.803304

11.774211

13.398125

11.791042

12.333595

12.483249

12.294691

11.820029

10.065469

12.191257

9.462444

11.52632

11.463148

9.80196

7.901348

8.216266

9.044022

12.088578

9.412593

8.826545

12.042841

8.545685

8.354535

11.502001

10.68203

11.484902

(Continued)

CTNND2

9.03388

Control

18.111416

17.034954

16.01196

15.761177

15.032014

14.796619

14.751841

14.710272

14.251518

14.023661

13.919523

13.87332

13.521647

13.492421

13.376745

13.228158

13.16062

13.144885

13.089962

12.957863

12.955015

12.94824

12.738785

12.597843

12.546266

12.409878

12.11682

12.047686

12.0056095

11.998627

11.918201

11.624274

11.354481

11.250544

11.122326

10.930079

10.921519

10.895491

10.587699

10.522251

10.452353

10.415711

10.304885

10.257294

10.250756

10.239203

10.234683

10.199277

10.153262

10.085579

9.970972

9.965946

9.903289

9.702747

9.636893

9.603488

10.7152

Gene	ID	Normalized intensity			
		Control	FH535		
MYHIO	4628	9.5496025	11.096066		
MMP15	4324	9.533566	8.395943		
DOCKI	1793	9.48097	11.021774		
PAK2	5062	9.287464	10.61245		
PLAUR	5329	9.265003	8.37788		
CDC27	996	9.129515	11.077047		
MSTIR	4486	9.085802	9.12538		
BAIAP2	10458	9.018734	8.004229		
PTK2	5747	8.939062	10.820772		
STAT3	6774	8.847785	7.9192953		
ARHGEF2	9181	8.798216	8.383045		
PKP4	8502	8.663319	9.734335		
MARK2	2011	8.612933	8.00314		
PVRL3	25945	8.582907	9.851074		
BCARI	9564	8.529809	7.7692404		
ARVCF	421	8.524339	8.364944		
SPTANI	6709	8.494044	7.7864056		
TJP2	9414	8.343918	7.3491254		
HCLSI	3059	8.263556	7.7210197		
WASFI	8936	8.178464	7.4462004		
HASI	3036	8.124433	7.6573296		
ADAMTS13	11093	8.074093	8.375932		
ESRI	2099	8.048168	7.405365		
OCLN	100506658	8.036663	9.494983		
WAS	7454	7.9598556	7.412658		
CTNNDI	1500	7.8659673	7.09317		
DOCK4	9732	7.829811	10.702755		
CDSN	1041	7.738298	7.3062844		
MAPIB	4131	7.7052383	10.589897		
MAPTE	4320	7.460847	7.2920337		
PXN	5829	7.426979	6.493304		
ACTN3	89	7.355976	6.6988516		
MTSSI	9788	7.3144355	8.826939		
VCAN	1462	7.045421	6.763195		
MMP9	4318	7.0101504	6.7540355		
VTN	7448	6.8925853	6.3992944		
EXOC2	55770	6.8692775	8.335709		
ECMI	1893	6.8224096	7.0186477		
TWISTI	7291	6.765423	6.105777		
ADAMTSI	9510	6.670437	7.5566187		
CASK	8573	6.554297	9.147331		
PLCGI	5335	6.326862	6.175169		
CTTN	2017	6.2022476	6.6959023		
FARP2	9855	5.4352922	5.775334		

in breast cancer and gastrointestinal stromal tumor.^{45,46} The motility-related gene *VEGFA* significantly increases the motility of pancreatic cancer cells. The vascular endothelial growth factor/vascular endothelial growth factor receptor (VEGF/VEGFR) inhibitors bevacizumab and sunitinib significantly decrease pancreatic cancer cell motility.⁴⁷ In our study, FH535 not only suppressed *VEGFA* expression

5.4170265

5.9111185

1501




Figure 3 (Continued)

							Е						
								5.58	10.22 18.43				
								Control	FH535	Gene ID	-0		
								Col	Η̈́Η	Ger	Gene	P	
										7431 7045 4830 3487 4478	IGFBP4	3487	\downarrow
D										4830 3487 4478	CAV1	857	\uparrow
_	5.34	9.7 16.21								5879 3855 7076	SNAI1	6615	↓*
	2	2	0							1290 6929 207	ITGA5	3678	\downarrow
	Control	FH535	Gene ID	Gene	•					3688 857 6615	TLN1	7094	Ļ
	Ŭ	ŧ			¹ D	•				3678	COL5A1	1289	\downarrow
			960 3693 3915	CD44	960	↑*				8189 1499 53827 655	NOTCH3	4854	Ļ
			3912 3675	LAMC1	3915	\uparrow				1289 79026	COL6A1	1291	\downarrow
			3688 3685 3655	ITGAV	3685	\uparrow				858 4854 83660	EGFR	1956	⊺ ↑
			3678 8910	ITGA6	3655	\uparrow				1291 3880 3480	WASL	8976	\ ↑
			3383 3691	ITGA5	3678	\downarrow				1956 2534 8976 800	CALD1	800	Ļ
			1499 1495 1307	COL5A1	1289	¥				3912	TGFB1	7040	\downarrow
			1289	COL6A1	1291					8324 5054 2885	GRB2	2885	Ť
			1490 1500	CTGF	1490	↓ ↑*				5962 6840	RDX SVIL	5962 6840	↑
			7059 3684 7057	ITGAM	3684					5339 6464 5997 4313	PLEC	5339	Ļ
			3679 4324			\downarrow				117178 1284	SHC1	5339 6464	\downarrow
			1294 3914	MMP15	4324	\downarrow				8613 7057 90952	SSX2IP	117178	Ŷ
			3036 11093 6687	COL7A1	1294	\downarrow				4855 6678 55591	COL4A2	1284	Ļ
			1303 999	SPG7	6687	\downarrow				4486 6774 51776	SPARC	6678	Ļ
			7373 3371 1462	COL12A1	1303	Ŷ				1294 57154 3914	VEZT	55591	↑ ↑
			7448 7123	ITGB2	3689	Ŷ				7145 6687 6654	ZAK	51776	↑
			3689 3673	ITGA2	3673	\uparrow				7456 649 2303	COL7A1	1294	Ļ
			6696 3909 6401	SELE	6401	\uparrow				1303 999 7373	SPG7	6687	Ļ
			1501 3672	ITGA1	3672	\uparrow				3371 3557 6663	COL12A1	1303	↑ 1
										1462 5728 4318	PTEN	5728	\uparrow
										4318 51678 6850 6696	MPP6	51678	\uparrow
										2065 3909	BMP2	650	\uparrow
										650 6655 7043	SOS2	6655	\uparrow

Figure 3 FH535 inhibited pancreatic cancer cell invasion.

Notes: (A) Dose-dependent inhibition by FH535 of PANC-1 and BxPC-3 cell invasion. (B) Microarray analysis of extracellular matrix degradation–related gene expression regulation upon FH535 treatment. (C) Dose-dependent inhibition by FH535 of PANC-1 and BxPC-3 cell adhesion. *P<0.05, **P<0.01, significant differences vs the respective control groups. (D) Microarray analysis of adhesion molecule–related gene expression regulation upon FH535 treatment. (E) Microarray analysis of EMT-related gene expression regulation upon FH535 treatment. Up and down arrows indicate gene expression significantly upregulated or downregulated, respectively, by twofold. Asterisks indicate genes downstream of the Wnt/ β -catenin pathway.

Abbreviation: EMT, epithelial-mesenchymal transition.

but also inhibited cell motility, suggesting the involvement of a similar mechanism.

To establish metastasis, tumor cells must traverse the basement membrane to reach the connective tissues. Accordingly, we investigated the anti-invasive effect of FH535. The Transwell assay proved that FH535 inhibited invasion. In vitro invasion can be divided into several steps, including matrix adhesion, matrix degradation, and EMT. We analyzed the expression of the genes involved in these steps using microarray and found that FH535 significantly downregulated the cell adhesion molecule ITGA5; *ITGA5* knockdown results in decreased adhesion in pancreatic cancer cells.⁴⁸ The ability of matrix metalloproteinases (MMPs) to degrade extracellular matrix proteins has been well characterized; therefore, they have been studied extensively to elucidate their involvement in both tumor development and progression. Different MMPs play different roles in tumorigenesis. MMP15 appears to be upregulated during colorectal tumorigenesis, and past research has shown stromal localization of MMP15 in the early phases of neoplastic transformation in colorectal cancer.⁴⁹ In our study, FH535 downregulated MMP15. Epithelial cells are characterized by welldeveloped junctions and apical–basolateral polarization; on the contrary, mesenchymal cells lack polarization due to the loss of an organized junctional layer. Cell metastasis is correlated with EMT. In the present study, FH535

FH535

 Table 7 Microarray analysis of adhesion molecule-related gene

 expression regulation upon FH535 treatment

Normalized intensity

Control

ID

Gene	ID	Normalized in	tensity	Gene
		Control	FH535	
TGFBI	7045	16.09069	15.894443	CD44
TIMP2	7077	14.796619	14.858342	ITGB5
TIMPI	7076	13.919523	13.2338505	LAMC
LAMCI	3915	13.492421	14.51922	LAMB
MMPI	4312	11.905035	12.887484	ITGA3
COLI 6A I	1307	11.647751	10.777789	ITGBI
COL5A1	1289	11.607744	10.272581	ITGAV
COL6A I	1291	11.396863	10.174638	
LAMBI	3912	10.813978	9.924841	ITGA6
CTGF	1490	10.809845	11.98555	ITGA5
THBS3	7059	10.1687765	9.736564	SGCE
MMP2	4313	10.153262	9.412593	ICAM I
COL4A2	1284	9.866227	8.850218	ITGB4
THBSI	7057	9.663341	9.193558	CTNN
MMP15	4324	9.533566	8.395943	CTNN
SPARC	6678	9.32407	8.289816	COLIE
COL7A1	1294	8.711706	7.6560946	COL5A
LAMB3	3914	8.550647	8.319239	COL6A
HASI	3036	8.124433	7.6573296	CTGF
ADAMTS13	11093	8.074093	8.375932	
SPG7	6687	7.799603	7.3888316	CTNN
MMPII	4320	7.460847	7.2920337	THBS3
COLI 2A I	1303	7.404812	8.422412	ITGAN
COLI 4A I	7373	7.3424816	6.805993	THBSI
TNC	3371	7.329479	6.564947	ITGA7
VCAN	1462	7.045421	6.763195	MMPI
MMP9	4318	7.0101504	6.7540355	COL7A
VTN	7448	6.8925853	6.3992944	LAMB
ECMI	1893	6.8224096	7.0186477	HASI
ADAMTSI	9510	6.670437	7.5566187	ADAM
CLEC3B	7123	6.6491346	6.5587797	SPG7
SPP I	6696	6.37645	6.842924	
LAMA3	3909	6.1783895	5.889333	COLI 2
				CDHI

downregulated Snail, which is upregulated during EMT.⁵⁰ In human colorectal cancer cells, overexpression of Snail induces not only EMT but also a cancer stem cell–like phenotype, which enhances cell migration and invasion in vitro and increases metastasis formation in vivo.⁵¹ Snail also plays an essential role in human pancreatic cancer progression and metastasis.^{52,53} In the clinical setting, overexpression of Snail was previously associated with poorer prognosis and a more invasive phenotype in many malignancies.^{54–56} We also detected the downregulation of TGFB1, a classic EMT stimulator.⁵⁷ TGFB1 overexpression is associated with early recurrence following resection and decreased survival;⁵⁸ consistent with our study, the suppression of TGFB1 activity in immune-deficient orthotopic mouse models of pancreatic cancer attenuated tumor growth and metastasis.^{59,60}

Besides metastasis, FH535 also induced G2/M arrest and inhibited pancreatic cancer cell proliferation. FH535

		Control	LU222
CD44	960	15.006962	16.199093
ITGB5	3693	13.888797	13.484464
LAMCI	3915	13.492421	14.51922
LAMBI	3912	12.817556	13.73472
ITGA3	3675	12.797894	12.391577
ITGBI	3688	12.738785	13.636554
ITGAV	3685	12.278682	14.3424
ITGA6	3655	12.273888	14.392418
ITGA5	3678	12.169847	10.866323
SGCE	8910	12.047686	12.282321
ICAMI	3383	12.0056095	11.118488
ITGB4	3691	11.982763	11.56935
CTNNBI	1499	11.900537	11.841962
CTNNAI	1495	11.841962	11.517105
COLI 6A I	1307	11.647751	10.777789
COL5A1	1289	11.607744	10.272581
COL6A I	1291	11.396863	10.174638
CTGF	1490	10.809845	11.98555
CTNND I	1500	10.622252	11.350482
THBS3	7059	10.1687765	9.736564
ITGAM	3684	10.003317	8.889115
THBSI	7057	9.663341	9.193558
ITGA7	3679	9.627002	8.878363
MMP15	4324	9.533566	8.395943
COL7A1	1294	8.711706	7.6560946
LAMB3	3914	8.550647	8.319239
HASI	3036	8.124433	7.6573296
ADAMTS13	11093	8.074093	8.375932
SPG7	6687	7.990712	6.850328
COLI 2A I	1303	7.404812	8.422412
CDHI	999	7.3595057	7.319695
COLI 4A I	7373	7.3424816	6.805993
TNC	3371	7.329479	6.564947
VCAN	1462	7.045421	6.763195
VTN	7448	6.8925853	6.3992944
CLEC3B	7123	6.6491346	6.5587797
ITGB2	3689	6.6435785	7.713477
ITGA2	3673	6.538141	10.171594
SPP I	6696	6.37645	6.842924
LAMA3	3909	6.1783895	5.889333
SELE	6401	5.8820415	7.629673
CTNND2	1501	5.4170265	5.9111185
ITGAI	3672	5.3547735	7.6031985

significantly upregulated the G2/M regulator gene *BCCIP* while downregulating the cell cycle regulatory genes *CCNG1* and *SERTAD1*. Human BCCIP, a protein that interacts with BRCA2 and CDKN1A (Cip1, p21), has been implicated in many cellular processes, including cell cycle regulation, DNA recombination and damage repair, telomere maintenance, embryonic development, and genomic stability.⁶¹⁻⁶³

Table 8Microarray analysis of EMT-related gene expressionregulation upon FH535treatment

TGFBI 7045 16.09069 15.8944 NME I 4830 15.692858 15.5730 IGFBP4 3487 14.852157 13.2468 MSN 4478 14.251518 15.1732 RACI 5879 14.251518 15.1132 KRT7 3855 14.184294 13.2838 COL5A2 1290 13.175857 12.8332 TCF3 6929 13.00084 12.2927 AKT1 207 12.957863 12.6591 ITGB1 3688 12.738785 13.6365 CAVI 857 12.61244 13.6177 SNAII 6615 12.28132 10.3857 ITAS 3678 12.169847 10.86458 SYMFK 8189 11.945259 12.3126 CTNNB1 1499 11.900537 11.8419 FXVD5 53827 11.88533 10.3709 CMAZ 858 11.523583 10.3709 CINA2 8560 11.40476	Gene	ID	Normalized intensity		
TGFBI 7045 16.09069 15.8944 NME I 4830 15.692858 15.5730 IGFBP4 3487 14.852157 13.2468 MSN 4478 14.251518 15.1732 RACI 5879 14.251518 15.1132 KRT7 3855 14.184294 13.2838 COL5A2 1290 13.175857 12.8332 TCF3 6929 13.00084 12.2927 AKT1 207 12.957863 12.6351 ITGB1 3688 12.738785 13.6365 CAVI 857 12.61244 13.6177 SNAII 6615 12.28132 10.8657 TLNI 7094 12.096641 10.6458 SYMPK 8189 11.945259 12.3126 CTNNBI 1499 11.900537 11.8419 FXD5 53827 11.88513 10.9382 COL5A1 1289 11.607744 10.2725 AHNAK 79026 11.605762 10.7859 CAV2 858 11.523583 10.3709			Control	FH535	
NME I 4830 15.692858 15.5730 IGFBP4 3487 14.852157 13.2468 MSN 4478 14.751841 15.3576 MSN 4478 14.251518 15.1132 KRT7 3855 14.184294 13.2338 COL5A2 1290 13.175857 12.8332 CGT3 6929 13.00084 12.2927 AKT1 207 12.957863 12.2591 ITGBI 3688 12.738785 13.6365 CAVI 857 12.61944 13.6177 SNAII 6615 12.28132 10.3857 TIGAS 3678 12.169847 10.8663 TLNI 7094 12.096641 10.6458 SYMPK 8189 11.93933 10.9382 CTNNBI 1499 11.900537 11.819 FXVD5 53827 11.8593933 10.9382 COL5A1 1289 11.607744 10.2725 AHNAK 79026 11.605762	VIM	7431	18.111416	18.417988	
IGFBP4 3487 14.852157 13.2468 MSN 4478 14.751841 15.3576 RACI 5879 14.251518 15.1132 KRT7 3855 14.184294 13.2850 TIMPI 7076 13.919523 13.2338 COLSA2 1290 13.175857 12.8332 TGF3 6929 13.00084 12.2927 AKT1 207 12.957863 12.2591 ITGB 3688 12.738785 13.6365 CAVI 857 12.61944 13.6177 SNAII 6615 12.28132 10.3857 TICA5 3678 12.169847 10.8663 TINI 7094 12.096641 10.6458 SYMPK 8189 11.942529 12.3126 CTINNBI 1499 11.900537 11.8419 FXVD5 53827 11.859393 10.9382 COLSAI 1289 11.607744 10.2725 AHNAK 79026 11.605762 10.7864 KRT19 3880 11.235938 10.3709	TGFBI	7045	16.09069	15.894443	
MSN 4478 14.751841 15.376 RAC1 5879 14.251518 15.1132 KRT7 3855 14.184294 13.2850 COL5A2 1290 13.175857 12.8332 TCF3 6929 13.00084 12.2927 AKT1 207 12.957863 12.2591 ITGBI 3688 12.738785 13.6365 CAVI 857 12.61244 13.6177 SNAII 6615 12.28132 10.3857 ITGAS 3678 12.169847 10.86453 SYMPK 8189 11.942529 12.3126 CTNNBI 1499 11.900537 11.8419 FXVDS 53827 11.859393 10.9806 BMP7 655 11.688513 10.378 CAV2 858 11.534644 11.7316 NOTCH3 4854 11.523583 10.3764 CAV2 83660 11.404076 10.8860 COL6A1 1291 11.3269585	NMEI	4830	15.692858	15.573043	
RACI 5879 14.251518 15.1132 KRT7 3855 14.184294 13.2680 TIMPI 7076 13.175857 12.2332 COLSA2 1290 13.175857 12.2332 CKT 2077 12.957863 12.2591 ITGB 3688 12.738785 13.6365 CAVI 857 12.61244 13.6177 SNAII 6615 12.28132 10.3857 TIGAS 3678 12.169847 10.8663 TLNI 7094 12.096641 10.6458 SYMPK 8189 11.942529 12.3126 CTNNBI 1499 11.900537 11.819 FXVD5 53827 11.65762 10.7859 CAV2 858 11.534644 11.7316 NOTCH3 4854 11.523583 10.3709 TLN2 83660 11.404076 10.8860 COL6A1 1291 11.386863 10.1746 GFIR 1956 11.23258	IGFBP4	3487	14.852157	13.246835	
KRT7 3855 14.184294 13.2850 TIMP I 7076 13.919523 13.2338 COL5A2 1290 13.175857 12.8332 TCF3 6929 13.00084 12.2927 AKT1 207 12.957863 12.2591 ITGBI 3688 12.738785 13.6365 CAVI 857 12.61244 13.6177 SNAII 6615 12.28132 10.3857 ITGAS 3678 12.169847 10.8663 TLN1 7094 12.096641 10.6458 SYMPK 8189 11.942529 12.3126 CTNNB1 1499 11.900537 11.8419 FXYD5 53827 11.859393 10.9866 COL5A1 1289 11.607744 10.2725 AHNAK 79026 11.605762 10.7859 CAV2 858 11.334644 11.7316 NOTCH3 4854 11.232583 10.3746 KRT19 3880 11.232583 </td <td>MSN</td> <td>4478</td> <td>14.751841</td> <td>15.357616</td>	MSN	4478	14.751841	15.357616	
TIMP1707613.91952313.2338COLSA2129013.17585712.8332TCF3692913.008412.2927AKT120712.95786312.2591ITGBI366812.73878513.6365CAV185712.6124413.6177SNAII661512.2813210.3857ITGA5367812.16984710.8663TLNI709412.09664110.6458SYMPK818911.94252912.3126CTNNBI149911.90053711.8419FXVD55382711.85939310.9806BMP765511.60851310.9382COLSAI128911.60774410.2725AHNAK7902611.60576210.7859CAV285811.53464411.7316NOTCH3485411.52358310.3709TLN28366011.40407610.8860COL6AI129111.39686310.1746KRT19388011.23950511.1019IGFIR348011.2326612.3335FYN253410.96611211.3256CALD I80010.92151912.2946LAMBI391210.8139789.92484TGFBI704010.71529.03388FZD7832410.7113249.90157SERPINEI505410.63518210.4523GRB2288510.6056139.41689RDX596210.52225112.1912SVL6	RACI	5879	14.251518	15.113209	
COLSA2 1290 13.175857 12.8332 TCF3 6929 13.00084 12.2927 AKT1 207 12.957863 12.2591 ITGBI 3688 12.738785 13.6365 CAVI 857 12.61244 13.6177 SNAII 6615 12.28132 10.3857 ITGA5 3678 12.169847 10.8663 TLNI 7094 12.096641 10.6458 SYMPK 8189 11.942529 12.3126 CTNNB1 1499 11.900537 11.841 FXYD5 53827 11.859393 10.9806 BMP7 655 11.605762 10.7859 CAV2 858 11.534644 11.731 NOTCH3 4854 11.523583 10.3709 TLN2 83660 11.404076 10.8860 COL6A1 1291 11.396863 10.1746 KRT19 380 11.23236 12.3335 FYN 2534 10.966112	KRT7	3855	14.184294	13.285099	
TCF3 6929 13.00084 12.2927 AKT1 207 12.957863 12.2591 ITGB1 3688 12.738785 13.6365 CAV1 857 12.61244 13.6177 SNAII 6615 12.28132 10.3857 ITGA5 3678 12.169847 10.8663 TLN1 7094 12.096641 10.6458 SYMPK 8189 11.942529 12.3126 CTNNB1 1499 11.900537 11.8419 FXYD5 53827 11.859393 10.9806 BMP7 655 11.668513 10.7325 AHNAK 79026 11.605762 10.7859 CAV2 858 11.534644 11.7316 NOTCH3 4854 11.523583 10.3709 TLN2 83660 11.404076 10.8860 COL6A1 1291 11.396863 10.1746 KRT19 3880 11.22326 12.3335 FYN 2534 10.930079	TIMPI	7076	13.919523	13.2338505	
AKT120712.95786312.2591ITGB I368812.73878513.6365CAV I85712.6124413.6177SNAII661512.2813210.3857ITGA5367812.16984710.8663TLNI709412.09664110.6458SYMPK818911.94252912.3126CTNNBI149911.90053711.8419FXVD55382711.85939310.9806BMP765511.60576210.7859COLSA1128911.60774410.2725AHNAK7902611.60576210.7859CAV285811.53464411.7316NOTCH3485411.52358310.3709TLN28366011.40407610.8860COL6A1129111.39686310.1746KRT19388011.236958512.1404EGFR195611.1232612.3335FYN253410.96611211.3258WASL897610.93007912.4832CALD I80010.92151912.2946LAMBI391210.8139789.2444TGFB1704010.71529.0388FZD7832410.7113249.90157SERPINE1505410.656139.41689RDX596210.52225112.1912SVIL684010.30488511.4631PLEC533910.3015599.20466SHCI64539.4334919.9762COL4A212	COL5A2	1290	13.175857	12.833253	
ITGB1 3688 12.738785 13.6365 CAVI 857 12.61244 13.6177 SNAII 6615 12.28132 10.3857 ITGA5 3678 12.1698477 10.8663 TLNI 7094 12.096641 10.6458 SYMPK 8189 11.942529 12.3126 CTNNB1 1499 11.900537 11.8419 FXYD5 53827 11.688513 10.9382 COLSAI 1289 11.607744 10.2725 AHNAK 79026 11.605762 10.7859 CAV2 858 11.534644 11.7316 NOTCH3 4854 11.523583 10.3709 TLN2 83660 11.404076 10.8860 COL6AI 1291 11.369585 11.1019 IGF1R 3480 11.23256 12.3335 FYN 2534 10.97152 9.03388 FZD7 8324 10.711324 9.0157 SERPINE1 5054 10.639182 10.4523 GRB2 2885 10.605613 9.41689 </td <td>TCF3</td> <td>6929</td> <td>13.00084</td> <td>12.29279</td>	TCF3	6929	13.00084	12.29279	
CAVI 857 12.61244 13.6177 SNAII 6615 12.28132 10.3857 ITGA5 3678 12.169847 10.8663 TLNI 7094 12.096641 10.6458 SYMPK 8189 11.942529 12.3126 CTNNB1 1499 11.900537 11.8419 FXYD5 53827 11.859393 10.9806 BMP7 655 11.688513 10.9382 COLSAI 1289 11.607744 10.2725 AHNAK 79026 11.605762 10.7859 CAV2 858 11.534644 11.7316 NOTCH3 4854 11.523583 10.3709 TLN2 83660 11.404076 10.8860 COL6AI 1291 11.396863 10.1746 KRT19 3880 11.22305 11.1019 IGF1R 3480 11.2369585 12.1404 EGFR 1956 11.12326 12.3335 FYN 2534 10.61912	AKTI	207	12.957863	12.259176	
SNAII 6615 12.28132 10.3857 ITGA5 3678 12.169847 10.8663 TLNI 7094 12.096641 10.6458 SYMPK 8189 11.942529 12.3126 CTNNBI 1499 11.900537 11.8419 FXD5 53827 11.859393 10.9806 BMP7 655 11.668513 10.9382 COL5A1 1289 11.607744 10.2725 AHNAK 79026 11.605762 10.7859 CAV2 858 11.534644 11.7316 NOTCH3 4854 11.523583 10.3709 TLN2 83660 11.404076 0.8860 COL6A1 1291 11.396863 10.1746 KRT19 3880 11.22369 12.1404 EGFR 1956 11.12236 12.3335 FYN 2534 10.960112 11.3258 CALD1 800 10.921519 12.2946 LAMB1 3912 10.813978	ITGBI	3688	12.738785	13.636554	
ITGA5367812.16984710.8663TLN1709412.09664110.6458SYMPK818911.94252912.3126CTNNB1149911.90053711.8419FXD55382711.85939310.9806BMP765511.68851310.9382COLSA1128911.60774410.2725AHNAK7902611.60576210.7859CAV285811.53464411.7316NOTCH3485411.52358310.3709TLN28366011.40407610.8860COL6A1129111.39686310.1746IGF1R348011.236958512.1404EGFR195611.12326612.3335FYN253410.96611211.3258WASL897610.93007912.4832CALD180010.92151912.2946LAMB1391210.8139789.92484FZD7832410.7113249.0157SERPINE1505410.63918210.4523GRB2288510.6056139.41689RDX596210.52225112.1912SVIL684010.30488511.4631PLEC533910.3015599.20466MMP2431310.1532629.41259SSX2IP11717810.14443211.1675COL4A212849.8662278.85053FHBS170579.6633419.19355SPARC66789.324078.28981VEZT	CAVI	857	12.61244	13.617725	
TLN1709412.09664110.6458SYMPK818911.94252912.3126CTNNB1149911.90053711.8419FXD55382711.85939310.9806BMP765511.60851310.9382COL5A1128911.60774410.2725AHNAK7902611.60576210.7859CAV285811.53464411.7316NOTCH3485411.52358310.3709TLN28366011.40407610.8860COL6A1129111.39686310.1746KRT19388011.28950511.1019IGF1R348011.236958512.1404EGFR195611.12232612.3335FYN253410.96611211.3258WASL897610.93007912.4832CALD180010.92151912.2946LAMB1391210.8139789.92484TGFB1704010.71529.03388FZD7832410.7113249.90157SERPINE1505410.63918210.4523GRB2288510.6056139.41689SX21P11717810.14443211.1675COL4A212849.8662278.85953RGS2599710.2572949.80196MMP2431310.1532629.41259SX21P11717810.14443211.1675COL4A212849.8662278.85021SSX21P11717810.14443211.1675	SNALL	6615	12.28132	10.385736	
SYMPK 8189 11.942529 12.3126 CTNNB1 1499 11.900537 11.8419 FXYD5 53827 11.859393 10.9806 BMP7 655 11.688513 10.9382 COL5A1 1289 11.607744 10.2725 AHNAK 79026 11.607762 10.7859 CAV2 858 11.534644 11.7316 NOTCH3 4854 11.523583 10.3709 TLN2 83660 11.404076 10.8860 COL6A1 1291 11.396863 10.1746 KRT19 3880 11.22365 12.1404 EGFR 1956 11.12236 12.3335 FYN 2534 10.966112 11.3258 CALD1 800 10.921519 12.2946 LAMB1 3912 10.813978 9.92484 TGFB1 7040 10.7152 9.03388 FZD7 8324 10.711324 9.90157 SERPINE1 5054 10.639182<	ITGA5	3678	12.169847	10.866323	
CTNNB1 1499 11.900537 11.8419 FXYD5 53827 11.859393 10.9806 BMP7 655 11.688513 10.9382 COL5A1 1289 11.607744 10.2725 AHNAK 79026 11.605762 10.7859 CAV2 858 11.534644 11.7316 NOTCH3 4854 11.523583 10.3709 TLN2 83660 11.404076 10.8860 COL6A1 1291 11.396863 10.1746 KRT19 3880 11.28505 11.1019 IGF1R 3480 11.22326 12.3335 FYN 2534 10.966112 11.3258 WASL 8976 10.930079 12.4832 CALD1 800 10.921519 12.2946 LAMB1 3912 10.813978 9.92484 TGFB1 7040 10.7152 9.0388 FZD7 8324 10.711324 9.0157 SERPINE1 5054 10.639182 10.4523 GRB2 2885 10.605613 9.41689	TLNI	7094	12.096641	10.645829	
FXYD5 53827 11.859393 10.9806 BMP7 655 11.688513 10.9382 COL5A1 1289 11.607744 10.2725 AHNAK 79026 11.605762 10.7859 CAV2 858 11.534644 11.7316 NOTCH3 4854 11.523583 10.3709 TLN2 83660 11.404076 10.8860 COL6A1 1291 11.396863 10.1746 KRT19 3880 11.2369585 12.1404 EGFR 1956 11.12326 12.3335 FYN 2534 10.966112 11.3258 WASL 8976 10.930079 12.4832 CALD1 800 10.921519 12.2946 LAMB1 3912 10.813978 9.92484 TGFB1 7040 10.7152 9.03388 FZD7 8324 10.639182 10.4523 GRB2 2885 10.605613 9.41689 RDX 5962 10.522251 12.1912 SVIL 6840 10.304885 11.4631	SYMPK	8189	11.942529	12.312602	
BMP765511.68851310.9382COL5A1128911.60774410.2725AHNAK7902611.60576210.7859CAV285811.53464411.7316NOTCH3485411.52358310.3709TLN28366011.40407610.8860COL6A1129111.39686310.1746KRT19388011.28950511.1019IGF1R348011.236958512.1404EGFR195611.1232612.3335FYN253410.96611211.3258WASL897610.93007912.4832CALD180010.92151912.2946LAMB1391210.8139789.92484TGFB1704010.71529.03388FZD7832410.7113249.90157SERPINE1505410.63918210.4523GRB2288510.6056139.41689RDX596210.52225112.1912SVIL684010.30488511.4631PLEC533910.3015599.20466SHC1646410.2876788.59563GS2599710.2572949.80196MMP2431310.1532629.41259SSX2IP11717810.14443211.1675COL4A212849.8662278.85021PPAP2B86139.7187319.95688THBSI70579.6633419.19355SFAM909529.4722618.95982NOTCH4 <t< td=""><td>CTNNBI</td><td>1499</td><td>11.900537</td><td>11.841962</td></t<>	CTNNBI	1499	11.900537	11.841962	
COLSA1 1289 11.607744 10.2725 AHNAK 79026 11.605762 10.7859 CAV2 858 11.534644 11.7316 NOTCH3 4854 11.523583 10.3709 TLN2 83660 11.404076 10.8860 COLSA1 1291 11.396863 10.1746 KRT19 3880 11.289505 11.1019 IGF1R 3480 11.2369585 12.1404 EGFR 1956 11.12326 12.3335 FYN 2534 10.966112 11.3258 WASL 8976 10.930079 12.4832 CALD1 800 10.7152 9.03388 FZD7 8324 10.711324 9.90157 SERPINE1 5054 10.639182 10.4523 GRB2 2885 10.605613 9.41689 RDX 5962 10.52251 12.1912 SVIL 6840 10.304885 11.4631 PLEC 5339 10.301559	FXYD5	53827	11.859393	10.980669	
AHNAK7902611.60576210.7859CAV285811.53464411.7316NOTCH3485411.52358310.3709TLN28366011.40407610.8860COL6A1129111.39686310.1746KRT19388011.23950511.1019IGF1R348011.236958512.1404EGFR195611.12326612.3335FYN253410.96611211.3258WASL897610.93007912.4832CALD180010.92151912.2946IGFB1704010.71529.03388FZD7832410.63918210.4523GRB2288510.6056139.41689RDX596210.5225112.1912SVIL684010.30488511.4631PLEC533910.3015599.20466SHC1646410.2876788.59563RGS2599710.2572949.80196MMP2431310.1532629.41259SSX2IP11717810.14443211.1675COL4A212849.8662278.85021PPAP2B86139.7187319.95588THBS170579.6633419.19355SSAM909529.4722618.95982NOTCH448559.4334919.70782SPARC66789.324078.28981VEZT555919.12849311.1954MST1R44869.0858029.12538STAT36774	BMP7	655	11.688513	10.938241	
CAV2 858 11.534644 11.7316 NOTCH3 4854 11.523583 10.3709 TLN2 83660 11.404076 10.8860 COL6A1 1291 11.396863 10.1746 KRT19 3880 11.289505 11.1019 IGF1R 3480 11.2369585 12.1404 EGFR 1956 11.12326 12.3335 FYN 2534 10.966112 11.3258 WASL 8976 10.930079 12.4832 CALD1 800 10.921519 12.2946 LAMB1 3912 10.813978 9.92484 TGFB1 7040 10.7152 9.03388 FZD7 8324 10.711324 9.90157 SERPINE1 5054 10.639182 10.4523 GRB2 2885 10.605613 9.41689 RDX 5962 10.522251 12.1912 SVIL 6840 10.304885 11.4631 PLEC 5339 10.301559 9.20466 SHC1 6464 10.287678 8.59563	COL5A1	1289	11.607744	10.272581	
NOTCH3485411.52358310.3709TLN28366011.40407610.8860COL6A1129111.39686310.1746KRT19388011.28950511.1019IGF1R348011.236958512.1404EGFR195611.1232612.3335FYN253410.96611211.3258WASL897610.93007912.4832CALD180010.92151912.2946LAMB1391210.8139789.92484TGFB1704010.71529.03388FZD7832410.7113249.90157SERPINE1505410.63918210.4523GRB2288510.6056139.41689RDX596210.52225112.1912SVIL684010.30488511.4631PLEC533910.3015599.20466SHC1646410.2876788.59563RGS2599710.2572949.80196MMP2431310.1532629.41259SSX2IP11717810.14443211.1675COL4A212849.8662278.85021PAP2B86139.7187319.95658NOTCH448559.4334919.70782SPARC66789.324078.28981VEZT555919.12849311.1954MST1R44869.0858029.12538STAT367748.8477857.91929ZAK517768.71943211.371COL7A112	AHNAK	79026	11.605762	10.785921	
TLN2 83660 11.404076 10.8860 COL6A1 1291 11.396863 10.1746 KRT19 3880 11.289505 11.1019 IGF1R 3480 11.2369585 12.1404 EGFR 1956 11.12326 12.3335 FYN 2534 10.966112 11.3258 WASL 8976 10.930079 12.4832 CALD1 800 10.921519 12.2946 LAMB1 3912 10.813978 9.92484 TGFB1 7040 10.7152 9.03388 FZD7 8324 10.711324 9.90157 SERPINE1 5054 10.639182 10.4523 GRB2 2885 10.605613 9.41689 RDX 5962 10.522251 12.1912 SVIL 6840 10.304885 11.4631 PLEC 5339 10.301559 9.20466 SHC1 6464 10.287678 8.59563 RGS2 5997 10.257294	CAV2	858	11.534644	11.731664	
COL6A1129111.39686310.1746KRT19388011.28950511.1019IGF1R348011.236958512.1404EGFR195611.12232612.3335FYN253410.96611211.3258WASL897610.93007912.4832CALD180010.92151912.2946LAMB1391210.8139789.92484TGFB1704010.71529.03388FZD7832410.7113249.90157SERPINE1505410.63918210.4523GRB2288510.6056139.41689RDX596210.52225112.1912SVIL684010.30488511.4631PLEC533910.3015599.20466SHC1646410.2876788.59563RGS2599710.2572949.80196MMP2431310.1532629.41259SSX2IP11717810.14443211.1675COL4A212849.8662278.85021PAP2B86139.7187319.95658THBS170579.6633419.19355ESAM909529.4722618.95982NOTCH448559.4334919.70782SPARC66789.324078.28981VEZT555919.12849311.1954MST1R44869.0858029.12338STAT367748.8477857.91929ZAK517768.71943211.371COL7A11294	NOTCH3	4854	11.523583	10.370972	
KRT19388011.28950511.1019IGF1R348011.236958512.1404EGFR195611.12232612.3335FYN253410.96611211.3258WASL897610.93007912.4832CALD180010.92151912.2946LAMB1391210.8139789.92484TGFB1704010.71529.03388FZD7832410.7113249.90157SERPINE1505410.65918210.4523GRB2288510.6056139.41689RDX596210.52225112.1912SVIL684010.30488511.4631PLEC533910.3015599.20466SHC1646410.2876788.59563RGS2599710.2572949.80196MMP2431310.1532629.41259SSX2IP11717810.14443211.1675COL4A212849.8662278.85021PPAP2B86139.7187319.95658THBS170579.6633419.19355ESAM909529.4722618.95982NOTCH448559.4334919.70782SPARC66789.324078.28981VEZT555919.12849311.1954MST1R44869.0858029.12538STAT367748.8477857.91929ZAK517768.71943211.371COL7A112948.7117067.6569SMURF157154	TLN2	83660	11.404076	10.886059	
IGF1R348011.236958512.1404EGFR195611.12232612.3335FYN253410.96611211.3258WASL897610.93007912.4832CALD180010.92151912.2946LAMB1391210.8139789.92484TGFB1704010.71529.03388FZD7832410.7113249.90157SERPINE1505410.63918210.4523GRB2288510.6056139.41689RDX596210.52225112.1912SVIL684010.30488511.4631PLEC533910.3015599.20466SHC1646410.2876788.59563RGS2599710.2572949.80196MMP2431310.1532629.41259SSX2IP11717810.14443211.1675COL4A212849.8662278.85021PPAP2B86139.7187319.95658THBS170579.6633419.19355ESAM909529.4722618.95982NOTCH448559.324078.28981VEZT555919.12849311.1954MST1R44869.0858029.12538STAT367748.8477857.91929ZAK517768.71943211.371COL7A112948.7117067.6569SMURF1571548.6292999.52253LAMB339148.5506478.31923	COL6A I	1291	11.396863	10.174638	
EGFR195611.12232612.3335FYN253410.96611211.3258WASL897610.93007912.4832CALD I80010.92151912.2946LAMB I391210.8139789.92484TGFB I704010.71529.03388FZD 7832410.7113249.90157SERPINE I505410.63918210.4523GRB2288510.6056139.41689RDX596210.52225112.1912SVIL684010.3048511.4631PLEC533910.3015599.20466SHC1646410.2876788.59563RGS2599710.2572949.80196MMP2431310.1532629.41259SSX2IP11717810.14443211.1675COL4A212849.8662278.85021PPAP2B86139.7187319.95658THBS170579.6633419.19355ESAM909529.4722618.95982NOTCH448559.324078.28981VEZT555919.12849311.1954MST1R44869.0858029.12538STAT367748.8477857.91929ZAK517768.71943211.371COL7A112948.7117067.65609SMURF1571548.6292999.52253LAMB339148.5506478.31923	KRT19	3880	11.289505	11.101922	
FYN253410.96611211.3258WASL897610.93007912.4832CALD I80010.92151912.2946LAMB I391210.8139789.92484TGFB I704010.71529.03388FZD 7832410.7113249.90157SERPINE I505410.63918210.4523GRB 2288510.6056139.41689RDX596210.52225112.1912SVIL684010.3048511.4631PLEC533910.3015599.20466SHC I646410.2876788.59563RGS2599710.2572949.80196MMP2431310.1532629.41259SSX2IP11717810.14443211.1675COL4A212849.8662278.85021PPAP2B86139.7187319.95658THBS I70579.6633419.19355ESAM909529.4722618.95982NOTCH448559.4334919.70782SPARC66789.324078.28981VEZT555919.12849311.1954MST1R44869.0858029.12538STAT367748.8477857.91929ZAK517768.71943211.371COL7A112948.7117067.65609SMURF1571548.6292999.52253LAMB339148.5506478.31923	IGFIR	3480	11.2369585	12.140446	
WASL897610.93007912.4832CALD I80010.92151912.2946LAMB I391210.8139789.92484TGFB I704010.71529.03388FZD 7832410.7113249.90157SERPINE I505410.63918210.4523GRB 2288510.6056139.41689RDX596210.52225112.1912SVIL684010.30488511.4631PLEC533910.3015599.20466SHC I646410.2876788.59563RGS2599710.2572949.80196MMP2431310.1532629.41259SSX2IP11717810.14443211.1675COL4A212849.8662278.85021PPAP2B86139.7187319.95658THBS170579.6633419.19355ESAM909529.4722618.95982NOTCH448559.4334919.70782SPARC66789.324078.28981VEZT555919.12849311.1954MST1R44869.0858029.12538STAT367748.8477857.91929ZAK517768.71943211.371COL7A112948.7117067.65609SMURF1571548.6292999.52253LAMB339148.5506478.31923	EGFR	1956	11.122326	12.333595	
CALD I80010.92151912.2946LAMB I391210.8139789.92484TGFB I704010.71529.03388FZD 7832410.7113249.90157SERPINE I505410.63918210.4523GRB 2288510.6056139.41689RDX596210.52225112.1912SVIL684010.30488511.4631PLEC533910.3015599.20466SHC I646410.2876788.59563RGS2599710.2572949.80196MMP2431310.1532629.41259SSX2IP11717810.14443211.1675COL4A212849.8662278.85021PPAP2B86139.7187319.95658THBS I70579.6633419.19355ESAM909529.4722618.95982NOTCH448559.4334919.70782SPARC66789.324078.28981VEZT555919.12849311.1954MSTIR44869.0858029.12538STAT367748.8477857.91929ZAK517768.71943211.371COL7AI12948.7117067.65609SMURFI571548.6292999.52253LAMB339148.5506478.31923	FYN	2534	10.966112	11.325876	
LAMB1391210.8139789.92484TGFB1704010.71529.03388FZD7832410.7113249.90157SERPINE1505410.63918210.4523GRB2288510.6056139.41689RDX596210.52225112.1912SVIL684010.30488511.4631PLEC533910.3015599.20466SHC1646410.2876788.59563RGS2599710.2572949.80196MMP2431310.1532629.41259SSX2IP11717810.14443211.1675COL4A212849.8662278.85021PPAP2B86139.7187319.95658THBS170579.6633419.19355ESAM909529.4722618.95982NOTCH448559.4334919.70782SPARC66789.324078.28981VEZT555919.12849311.1954MST1R44869.0858029.12538STAT367748.8477857.91929ZAK517768.71943211.371COL7A112948.7117067.65609SMURF1571548.6292999.52253LAMB339148.5506478.31923		8976	10.930079	12.483249	
TGFB1704010.71529.03388FZD7832410.7113249.90157SERPINE1505410.63918210.4523GRB2288510.6056139.41689RDX596210.52225112.1912SVIL684010.30488511.4631PLEC533910.3015599.20466SHC1646410.2876788.59563RGS2599710.2572949.80196MMP2431310.1532629.41259SSX2IP11717810.14443211.1675COL4A212849.8662278.85021PPAP2B86139.7187319.95658THBS170579.6633419.19355ESAM909529.4722618.95982NOTCH448559.4334919.70782SPARC66789.324078.28981VEZT555919.12849311.1954MST1R44869.0858029.12538STAT367748.8477857.91929ZAK517768.71943211.371COL7A112948.7117067.65609SMURF1571548.6292999.52253LAMB339148.5506478.31923	CALD I	800	10.921519	12.294691	
FZD7832410.7113249.90157SERPINE I505410.63918210.4523GRB2288510.6056139.41689RDX596210.52225112.1912SVIL684010.30488511.4631PLEC533910.3015599.20466SHC1646410.2876788.59563RGS2599710.2572949.80196MMP2431310.1532629.41259SSX2IP11717810.14443211.1675COL4A212849.8662278.85021PPAP2B86139.7187319.95658THBS170579.6633419.19355ESAM909529.4722618.95982NOTCH448559.4334919.70782SPARC66789.324078.28981VEZT555919.12849311.1954MST1R44869.0858029.12538STAT367748.8477857.91929ZAK517768.71943211.3371COL7A112948.7117067.65609SMURF1571548.6292999.52253LAMB339148.5506478.31923	LAMBT	3912	10.813978	9.924841	
SERPINE I505410.63918210.4523GRB2288510.6056139.41689RDX596210.52225112.1912SVIL684010.30488511.4631PLEC533910.3015599.20466SHC1646410.2876788.59563RGS2599710.2572949.80196MMP2431310.1532629.41259SSX2IP11717810.14443211.1675COL4A212849.8662278.85021PPAP2B86139.7187319.95658THBS170579.6633419.19355ESAM909529.4722618.95982NOTCH448559.4334919.70782SPARC66789.324078.28981VEZT555919.12849311.1954MST1R44869.0858029.12538STAT367748.8477857.91929ZAK517768.71943211.3371COL7A112948.7117067.65609SMURF1571548.6292999.52253LAMB339148.5506478.31923	TGFBI	7040	10.7152	9.03388	
GRB2288510.6056139.41689RDX596210.52225112.1912SVIL684010.30488511.4631PLEC533910.3015599.20466SHC1646410.2876788.59563RGS2599710.2572949.80196MMP2431310.1532629.41259SSX2IP11717810.14443211.1675COL4A212849.8662278.85021PPAP2B86139.7187319.95658THBS170579.6633419.19355ESAM909529.4722618.95982NOTCH448559.4334919.70782SPARC66789.324078.28981VEZT555919.12849311.1954MST1R44869.0858029.12538STAT367748.8477857.91929ZAK517768.71943211.3371COL7A112948.7117067.65609SMURF1571548.6292999.52253LAMB339148.5506478.31923		8324	10.711324	9.901575	
RDX596210.52225112.1912SVIL684010.30488511.4631PLEC533910.3015599.20466SHC1646410.2876788.59563RGS2599710.2572949.80196MMP2431310.1532629.41259SSX2IP11717810.14443211.1675COL4A212849.8662278.85021PPAP2B86139.7187319.95658THBS170579.6633419.19355ESAM909529.4722618.95982NOTCH448559.4334919.70782SPARC66789.324078.28981VEZT555919.12849311.1954MSTIR44869.0858029.12538STAT367748.8477857.91929ZAK517768.71943211.3371COL7A112948.7117067.65609SMURF1571548.6292999.52253LAMB339148.5506478.31923	SERPINEI			10.452353	
SVIL 6840 10.304885 11.4631 PLEC 5339 10.301559 9.20466 SHC1 6464 10.287678 8.59563 RGS2 5997 10.257294 9.80196 MMP2 4313 10.153262 9.41259 SSX2IP 117178 10.144432 11.1675 COL4A2 1284 9.866227 8.85021 PPAP2B 8613 9.718731 9.95658 THBS1 7057 9.663341 9.19355 ESAM 90952 9.472261 8.95982 NOTCH4 4855 9.433491 9.70782 SPARC 6678 9.32407 8.28981 VEZT 55591 9.128493 11.1954 MSTIR 4486 9.085802 9.12538 STAT3 6774 8.847785 7.91929 ZAK 51776 8.719432 11.3371 COL7A1 1294 8.711706 7.65609 SMURF1 57154 8.629299				9.416897	
PLEC533910.3015599.20466SHC1646410.2876788.59563RGS2599710.2572949.80196MMP2431310.1532629.41259SSX2IP11717810.14443211.1675COL4A212849.8662278.85021PPAP2B86139.7187319.95658THBS170579.6633419.19355ESAM909529.4722618.95982NOTCH448559.4334919.70782SPARC66789.324078.28981VEZT555919.12849311.1954MSTIR44869.0858029.12538STAT367748.8477857.91929ZAK517768.71943211.3371COL7AI12948.7117067.65609SMURFI571548.6292999.52253LAMB339148.5506478.31923				12.191257	
SHC1646410.2876788.59563RGS2599710.2572949.80196MMP2431310.1532629.41259SSX2IP11717810.14443211.1675COL4A212849.8662278.85021PPAP2B86139.7187319.95658THBS170579.6633419.19355ESAM909529.4722618.95982NOTCH448559.4334919.70782SPARC66789.324078.28981VEZT555919.12849311.1954MSTIR44869.0858029.12538STAT367748.8477857.91929ZAK517768.71943211.3371COL7AI12948.7117067.65609SMURFI571548.6292999.52253LAMB339148.5506478.31923				11.463148	
RGS2599710.2572949.80196MMP2431310.1532629.41259SSX2IP11717810.14443211.1675COL4A212849.8662278.85021PPAP2B86139.7187319.95658THBS170579.6633419.19355ESAM909529.4722618.95982NOTCH448559.4334919.70782SPARC66789.324078.28981VEZT555919.12849311.1954MSTIR44869.0858029.12538STAT367748.8477857.91929ZAK517768.71943211.3371COL7AI12948.7117067.65609SMURFI571548.6292999.52253LAMB339148.5506478.31923			10.301559	9.204668	
MMP2431310.1532629.41259SSX2IP11717810.14443211.1675COL4A212849.8662278.85021PPAP2B86139.7187319.95658THBS170579.6633419.19355ESAM909529.4722618.95982NOTCH448559.4334919.70782SPARC66789.324078.28981VEZT555919.12849311.1954MSTIR44869.0858029.12538STAT367748.8477857.91929ZAK517768.71943211.3371COL7AI12948.7117067.65609SMURFI571548.6292999.52253LAMB339148.5506478.31923				8.595637	
SSX2IP11717810.14443211.1675COL4A212849.8662278.85021PPAP2B86139.7187319.95658THBS170579.6633419.19355ESAM909529.4722618.95982NOTCH448559.4334919.70782SPARC66789.324078.28981VEZT555919.12849311.1954MSTIR44869.0858029.12538STAT367748.8477857.91929ZAK517768.71943211.3371COL7AI12948.7117067.65609SMURFI571548.6292999.52253LAMB339148.5506478.31923					
COL4A212849.8662278.85021PPAP2B86139.7187319.95658THBS170579.6633419.19355ESAM909529.4722618.95982NOTCH448559.4334919.70782SPARC66789.324078.28981VEZT555919.12849311.1954MSTIR44869.0858029.12538STAT367748.8477857.91929ZAK517768.71943211.3371COL7A112948.7117067.65609SMURF1571548.6292999.52253LAMB339148.5506478.31923				9.412593	
PPAP2B86139.7187319.95658THBS170579.6633419.19355ESAM909529.4722618.95982NOTCH448559.4334919.70782SPARC66789.324078.28981VEZT555919.12849311.1954MST1R44869.0858029.12538STAT367748.8477857.91929ZAK517768.71943211.3371COL7A112948.7117067.65609SMURF1571548.6292999.52253LAMB339148.5506478.31923				11.167568	
THBS170579.6633419.19355ESAM909529.4722618.95982NOTCH448559.4334919.70782SPARC66789.324078.28981VEZT555919.12849311.1954MST1R44869.0858029.12538STAT367748.8477857.91929ZAK517768.71943211.3371COL7A112948.7117067.65609SMURF1571548.6292999.52253LAMB339148.5506478.31923				8.850218	
ESAM909529.4722618.95982NOTCH448559.4334919.70782SPARC66789.324078.28981VEZT555919.12849311.1954MST1R44869.0858029.12538STAT367748.8477857.91929ZAK517768.71943211.3371COL7A112948.7117067.65609SMURF1571548.6292999.52253LAMB339148.5506478.31923					
NOTCH4 4855 9.433491 9.70782 SPARC 6678 9.32407 8.28981 VEZT 55591 9.128493 11.1954 MST1R 4486 9.085802 9.12538 STAT3 6774 8.847785 7.91929 ZAK 51776 8.719432 11.3371 COL7A1 1294 8.711706 7.65609 SMURF1 57154 8.629299 9.52253 LAMB3 3914 8.550647 8.31923					
SPARC66789.324078.28981VEZT555919.12849311.1954MST1R44869.0858029.12538STAT367748.8477857.91929ZAK517768.71943211.3371COL7A112948.7117067.65609SMURF1571548.6292999.52253LAMB339148.5506478.31923					
VEZT555919.12849311.1954MST1R44869.0858029.12538STAT367748.8477857.91929ZAK517768.71943211.3371COL7A112948.7117067.65609SMURF1571548.6292999.52253LAMB339148.5506478.31923				9.707824	
MST1R44869.0858029.12538STAT367748.8477857.91929ZAK517768.71943211.3371COL7A112948.7117067.65609SMURF1571548.6292999.52253LAMB339148.5506478.31923					
STAT367748.8477857.91929ZAK517768.71943211.3371COL7A112948.7117067.65609SMURF1571548.6292999.52253LAMB339148.5506478.31923				11.195451	
ZAK517768.71943211.3371COL7A I12948.7117067.65609SMURF I571548.6292999.52253LAMB339148.5506478.31923					
COL7A112948.7117067.65609SMURF1571548.6292999.52253LAMB339148.5506478.31923				7.9192953	
SMURF1571548.6292999.52253LAMB339148.5506478.31923				11.337164	
LAMB3 3914 8.550647 8.31923				7.6560946	
				9.522539	
INSI 7145 8.064375 7.53036				8.319239	
	INST	7145	8.064375	7.5303655 (Continued)	

Gene	ID	Normalized intensity		
		Control	FH535	
SPG7	6687	7.990712	6.850328	
SOST	6654	7.9648976	7.5355105	
WIPFI	7456	7.8996034	7.0742846	
BMPI	649	7.73736	6.776738	
FOXC2	2303	7.5557323	6.690961	
COLI 2A I	1303	7.404812	8.422412	
CDHI	999	7.3595057	7.319695	
COLI 4A I	7373	7.3424816	6.805993	
TNC	3371	7.329479	6.564947	
ILI RN	3557	7.2758436	6.734858	
SOX10	6663	7.0939784	6.8492174	
VCAN	1462	7.045421	6.763195	
PTEN	5728	7.0376005	9.120998	
MMP9	4318	7.0101504	6.7540355	
MPP6	51678	6.9906545	8.912582	
SYK	6850	6.4246235	6.223468	
SPP I	6696	6.37645	6.842924	
ERBB3	2065	6.178696	5.9926624	
LAMA3	3909	6.1783895	5.889333	
BMP2	650	6.0141077	7.1390386	
SOS2	6655	5.6132765	8.797646	
TGFB3	7043	5.5891886	6.0552535	

Abbreviation: EMT, epithelial-mesenchymal transition.

BCCIP knockdown and concomitant p53 deletion causes rapid development of medulloblastomas, which have a wide spectrum of alterations involving the Sonic hedgehog pathway, consistent with the caretaker responsibility of BCCIP in genomic integrity.⁶⁴ BCCIP expression is downregulated in human ovarian cancer, renal cell carcinoma, and colorectal cancer tissues, suggesting that the gene plays a role in the pathogenesis of these cancers.⁶³ The positive expression rate and intensity of CCNG1 in gastric carcinoma is significantly correlated with tumor differentiation. Elevated amounts of CCNG1 are frequently detected in malignant tissue tumors, including astrocytoma; melanoma; carcinoma of the esophagus, lung, and breast; and cancer of the cervix, uterus, and ovary.65 It plays a pivotal role in hepatocellular carcinoma metastasis and may be a novel prognostic biomarker and therapeutic target.⁶⁶ SERTAD1 is involved in positive regulation of the cell cycle and proliferation;^{67,68} accordingly, its expression is upregulated in several tumor types.^{69,70} Studies indicate that SERTAD1 promotes proliferation by binding to the transcription factor E2F1 and by enhancing its transcriptional activity.71 Experimental overexpression of SERTAD1 provoked hyperproliferation,⁷² genomic instability,68 and inhibition of apoptosis.73

We demonstrated that FH535 significantly inhibits pancreatic cancer cell metastasis by suppressing migration, invasion, and adhesion and induces the accumulation of cells in the G2/M phase to suppress proliferation. These results suggest that FH535 is a potential candidate for pancreatic cancer treatment. Some of the identified genes that responded to FH535 are well-established direct targets of the Wnt/ β -catenin pathway. However, it has not been proven that the other identified genes are located downstream of the pathway. FH535 might affect the expression of these genes through the Wnt/ β -catenin pathway indirectly or in

a β -catenin independent manner. In fact, FH535 not only antagonizes β -catenin/TCF-mediated transcription but also inhibits recruitment of the coactivators glucocorticoid receptor-interacting protein 1 (GRIP1) and β -catenin to peroxisome proliferator-activated receptor (PPAR) δ and PPAR γ ,¹⁰ suggesting that these mechanisms could also be involved in the anti-cancer effect of FH535.




Figure 4 (Continued)

e 37 tr				regulation upon 20 μM FH535			
10.49 16.28 10.29 12 10.29 12 10.29 12 10.29 12 10.29 12 10.29 12 10.29 10 10.28 12 10.28 12 10.29 12 10.	ene ID		Gene	ID	Normalized in		
4609 1164 387 ///		\downarrow *			Control	FH535	
387 332 91 9133			МҮС	4609	16.268158	15.204586	
9133 CDF	(N2D 1032	↓ ↓	CKS2	1164	15.878164	15.394571	
	(N1C 1028	¥	RHOA	387	15.761177	14.786651	
1647 1028 DDI 5111		¥	BIRC5	332	14.757564	14.219355	
1163 4172 SEF 9055 ON	RTAD1 29950	$\stackrel{\vee}{\uparrow}$	CCNBI	891	14.478785	14.022737	
9055 4085 983 804 983 804	_3 26354 SSF1 11186	Ļ	CCNB2	9133	14.019871	14.271269	
		\downarrow	KPNA2	3838	13.950185	14.971469	
3481 207 26354 3688 CDC		\downarrow	CDK4	1019	13.87332	13.635977	
11186	.3 8452	<u>↑</u>	CDKN2D	1032	13.839806	12.513427	
997 7029 FOS	SL1 8061	↓*	GADD45A	1647	13.765451	13.130958	
1033 5604 FOX			CDKNIC	1028	13.694702	12.537176	
1022 COL 997 FOS 991 1033 FOS 5604 FOS 8452 PDF 3611 209 WE		$\stackrel{\vee}{\uparrow}$	PCNA	5111	13.611973	13.2414665	
3611 2309 4331 4331		J.	CKSIB	1163	13.609195	12.845673	
4331 3725 5164 1499	RKB 9212 P1R15A 23645	Ť	MCM3	4172	13.580797	13.911951	
1499 PPF 4171 CC/ 33645 RAL 33645 RAL 33645 RAL 3031 ECO 5050 CDO 4950 CDO 4950 RB1 5888 BCO 4970 CDO 5888 RCD 4970 CDO 5888 RCD 5888 RCD 5885 RAL 5885 F2F 5955 PKL 5955 E2F		↓ *	PRCI		13.4114275		
23645 9656 RAL		Ļ		9055		14.32471	
1031 896 EGF	R 1956	↑ *	MAD2L1	4085	13.297964	12.867024	
1029 6790 CDC		↑ ,	CDKI	983	13.286596	13.600226	
5810 4853 BCC		↑ ↑	DDIT3	1649	13.135856	11.871853	
¹⁹⁵⁶ 1020 RB1 5888		↑ I	SERTAD I	29950	13.060848	11.212	
890 4173 GRI		↓ 	IGF2	3481	13.0203	13.799717	
8881 PPA 56647 995		Ť	AKTI	207	12.957863	12.259176	
5925 892 1025 E2F		Ť	GNL3	26354	12.891848	14.223899	
2885 472 8493 CCI		\downarrow	ITGBI	3688	12.738785	13.636554	
	D2L2 10459	\downarrow	RASSFI	11186	12.559567	11.458946	
1871 900 SHC	6464	Ļ	CDK7	1022	12.553116	13.288865	
907 907 908 904 904 904 904 904 904 904 904		Ť	CDC34	997	12.53036	11.302476	
6464 RU	/BL1 8607	¥	TFDP2	7029	12.527303	12.6644745	
1017 8607 SKF 6502 ALL		$\stackrel{\downarrow}{\uparrow}$	CDC20	991	12.526335	11.232994	
6502 836 196		*	CDKN3	1033	12.486179	12.966997	
5883 5036 11200 3630 RBE		Ť	MAP2KI	5604	12.483637	11.714967	
3630 RBE 585 6477 MAR		Ļ					
901 5932 CDF	(5RAP2 55755	↑	CUL3	8452	12.389215	13.715795	
5595 7027 MKI	67 4288	\downarrow	FOSLI	8061	12.344017	11.102832	
55755 CUL	.1 8454	T ↑	ILK	3611	12.11682	11.583433	
901 5932 CDF 5595 NKI 55755 CUL 55755 CUL 4288 RBL 3398 RBL		1	FOXO3	2309	12.095011	13.865094	
5934 EZF		Ť	MNATI	4331	12.074865	12.456777	
51512 PIN 1111	<i>(5RAP1</i> 51654	Ļ	JUN	3725	12.038464	12.673436	
83667 ATC		↑	PDK2	5164	11.944916	10.781894	
993 4193 CDF	KN1A 1026	Ļ	CTNNBI	1499	11.900537	11.841962	
51654 8312 CDF	KN1B 1027	\downarrow	WEE I	7465	11.894105	13.381722	
545 4174 1026 TSC		↑ ↑	MCM2	4171	11.862871	11.269842	
6654 1027 2765		↑ ↑	AURKB	9212	11.800928	9.697033	
2765 7248 CUL 672 DTC		\uparrow	PPP I R I 5A	23645	11.676006	10.124018	
672 8453 3925 1024 MDI		Ť	MDCI	9656	11.649198	10.940614	
25 5728 RBL		Ť	CDKN2C	1031	11.6150875	11.096327	
5728 RDL 4194 BM		↑	CCND3	896	11.576098	10.075832	
5933 894 SOX		↑ *					
		↑ *	CCNEI	898	11.407219	11.045229	
84126 DTC			CDKNDA	1000	11 242020		
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	324	↑	CDKN2A	1029	11.343829	11.097562	
84126 DTC	324		CDKN2A AURKA RAD I	1029 6790 5810	.343829 .181647 .162613	11.097562 10.961699 9.890079	

EGFR

CDK5

RAD51

CCNA2

MCM4

CDC16

1956

1020

5888

890

4173

8881

Notes: (A) Dose- and time-dependent inhibition by FH535 of PANC-1 and BxPC-3 cell growth. (B) Dose-dependent inhibition by FH535 of the clone formation ability

of BxPC-3 cells. *P<0.05, **P<0.01, significant differences vs the respective control groups. (C) Significant dose-dependent G2/M arrest following FH535 treatment in BxPC-3 cells. (D) Microarray analysis of cell cycle-related gene expression regulation upon 20 μM FH535 treatment. Up and down arrows indicate gene expression significantly upregulated or downregulated, respectively, by twofold. Asterisks indicate genes downstream of the Wnt/ β -catenin pathway. Abbreviation: h, hours.

(Continued)

12.333595

10.542482

10.784544

10.9871645

11.05679

13.084003

11.122326

11.117936

11.1082325

10.911861

10.849212

10.808938

Table 9 (Continued)

Gene	ID	Normalized intensity		
		Control FH535		
BCCIP	56647	10.778181	12.021907	
CDC25C	995	10.672214	10.564099	
RBI	5925	10.640414	12.741512	
CCNC	892	10.610059	10.50804	
CDK9	1025	10.606858	9.6394415	
GRB2	2885	10.605613	9.416897	
ATM	472	10.5960865	9.790577	
PPMID	8493	10.580978	9.338833	
CCNDI	595	10.543621	10.14267	
PKDI	5310	10.471296	9.29677	
E2F3	1871	10.412796	12.061844	
CCNGI	900	10.409301	9.063653	
CDK5R1	8851	10.322197	10.292204	
PDKI	5163	10.321034	10.933424	
MAD2L2	10459	10.306548	9.040705	
SHCI	6464	10.287678	8.595637	
CCNTI	904	10.17827	11.456285	
CDK2	1017	10.10528	9.357359	
RUVBLI	8607	10.000026	8.814938	
SKP2	6502	9.937107	8.872935	
CASP3	836	9.893856	10.658698	
AHR	196	9.886938	11.936481	
RAD9A	5883	9.855825	8.961951	
PA2G4	5036	9.737894	8.966842	
CHEK2	11200	9.726725	10.255492	
INS	3630	9.673779	8.813154	
BBS4	585	9.597437	9.65494	
SIAH I	6477	9.530121	9.295226	
CCNG2	901	9.4692955	8.337656	
RBBP8	5932	9.454372	12.631638	
MAPK3	5595	9.447224	7.818405	
TFDPI	7027	9.4434185	9.030092	
E2FI	1869	9.397123	8.754342	
CDK5RAP2	55755	9.390803	10.79269	
MAPKI	5594	9.240688	9.218932	
MKI67	4288	9.233824	8.092867	
ID2	3398	9.226584	8.999163	
CULI	8454	9.221058	10.794849	
RBL2	5934	9.160267	10.348637	
IAG2	3714	9.075178	8.140677	
GTSE I	51512	9.04477	8.488665	
CHEKI	1111	9.04231	9.651725	
E2F4	1874	9.035055	8.016477	
G0S2	50486	9.032754	8.410861	
SESN2	83667	8.951754	8.138044	
PTK2	5747	8.939062	10.820772	
CDC25A	993	8.677163	8.042739	
MDM2	4193	8.622698	7.73673	
CDK5RAP1	51654	8.508385	6.9220624	
AXINI	8312	8.351635	7.6164603	
ATR	545	8.152882	11.634625	
MCM5	4174	8.055058	7.4200873	
CDKNIA	1026	8.007444	6.7135	
SOST	6654	7.9648976	7.5355105	
CDKNIB	1027	7.8906517	6.7354736	
GML	2765	7.8596773	6.9595275	

Gene	ID	Normalized intensity		
		Control	FH535	
TSCI	7248	7.6562896	9.700143	
BRCAI	672	7.620017	10.24544	
CUL2	8453	7.566332	9.5496025	
STMNI	3925	7.5155845	6.8102884	
CDK8	1024	7.5133963 6.916		
TERT	7015	7.4070444	7.4882307	
ABLI	25	7.3099413	6.6226487	
PTEN	5728	7.0376005	9.120998	
MDM4	4194	6.996299	8.63818	
HUSI	3364	6.976554	7.3689637	
RBLI	5933	6.7265186	8.035306	
CCND2	894	6.3239446	5.996339	
BMP2	650	6.0141077	7.1390386	
ATRIP	84126	5.912352	6.682503	
CDC6	990	5.8019896	6.064807	
SOX2	6657	5.6166873	6.7975965	
PTGS2	5743	5.5262737	7.601541	
APC	324	5.3153567	6.5241365	
BTRC	8945	5.3152456	7.7473273	

Acknowledgments

Table 9 (Continued)

This study was supported by the National Natural Science Foundation of China (grant nos 81472296, 81101867, 81272542, 81200369, and 81372443), the CSPAC-Celgene Foundation, the China International Medical Foundation (grant no CIMF-F-H001-057), the Special Foundation of Clinical Medicine of Jiangsu Provincial Bureau of Science and Technology (grant no BL2014039), the Scientific Research Project of Jiangsu Provincial Bureau of Traditional Chinese Medicine (grant no L213236), the Medical Scientific Research Project of Jiangsu Provincial Bureau of Health (grant no Z201206), the Special Foundation of Wu Jieping Medical Foundation for Clinical Scientific Research (grant nos 320.6753.1225 and 320.6750.12242), the Science and Education for Health Foundation of Suzhou for Youth (grant nos SWKQ1003 and SWKQ1011), the Science and Technology Project Foundation of Suzhou (grant nos SYS201112, SYSD2012137, and SYS201335), the Science and Technology Foundation of Suzhou Xiangcheng (grant nos SZXC2012-70 and XJ201451), and a project founded by the priority academic program development of Jiangsu higher education institutions.

Disclosure

The authors report no conflicts of interest in this work.

References

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56(2):106-130.

2. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet. 2004;363(9414):1049-1057.

- Bosetti C, Bertuccio P, Malvezzi M, et al. Cancer mortality in Europe, 2005–2009, and an overview of trends since 1980. *Ann Oncol.* 2013; 24(10):2657–2671.
- Cai HH, Sun YM, Miao Y, et al. Aberrant methylation frequency of TNFRSF10C promoter in pancreatic cancer cell lines. *Hepatobiliary Pancreat Dis Int.* 2011;10(1):95–100.
- Iida J, Wilhelmson KL, Price MA, et al. Membrane type-1 matrix metalloproteinase promotes human melanoma invasion and growth. *J Invest Dermatol.* 2004;122(1):167–176.
- Eisenmann KM, McCarthy JB, Simpson MA, et al. Melanoma chondroitin sulphate proteoglycan regulates cell spreading through Cdc42, Ack-1 and p130cas. *Nat Cell Biol.* 1999;1(8):507–513.
- Vaid M, Prasad R, Sun Q, Katiyar SK. Silymarin targets beta-catenin signaling in blocking migration/invasion of human melanoma cells. *PLoS One*. 2011;6(7):e23000.
- Iida J, Pei D, Kang T, et al. Melanoma chondroitin sulfate proteoglycan regulates matrix metalloproteinase-dependent human melanoma invasion into type I collagen. *J Biol Chem.* 2001;276(22): 18786–18794.
- 9. Clevers H. Wnt/beta-catenin signaling in development and disease. *Cell*. 2006;127(3):469–480.
- Handeli S, Simon JA. A small-molecule inhibitor of Tcf/beta-catenin signaling down-regulates PPARgamma and PPARdelta activities. *Mol Cancer Ther.* 2008;7(3):521–529.
- 11. Iida J, Dorchak J, Lehman JR, et al. FH535 inhibited migration and growth of breast cancer cells. *PLoS One*. 2012;7(9):e44418.
- Ren J, Wang R, Song H, Huang G, Chen L. Secreted frizzled related protein 1 modulates taxane resistance of human lung adenocarcinoma. *Mol Med.* 2014;20:164–178.
- Hannigan G, Troussard AA, Dedhar S. Integrin-linked kinase: a cancer therapeutic target unique among its ILK. *Nat Rev Cancer*. 2005; 5(1):51–63.
- Legate KR, Montanez E, Kudlacek O, Fassler R. ILK, PINCH and parvin: the tIPP of integrin signalling. *Nat Rev Mol Cell Biol*. 2006;7(1): 20–31.
- Palacios F, Price L, Schweitzer J, Collard JG, D'Souza-Schorey C. An essential role for ARF6-regulated membrane traffic in adherens junction turnover and epithelial cell migration. *EMBO J*. 2001;20(17): 4973–4986.
- Pece S, Gutkind JS. E-cadherin and Hakai: signalling, remodeling or destruction? *Nat Cell Biol*. 2002;4(4):E72–E74.
- 17. D'Souza-Schorey C. Disassembling adherens junctions: breaking up is hard to do. *Trends Cell Biol.* 2005;15(1):19–26.
- Tsukita S, Furuse M, Itoh M. Multifunctional strands in tight junctions. Nat Rev Mol Cell Biol. 2001;2(4):285–293.
- Cheng CY, Mruk DD. Cell junction dynamics in the testis: sertoli-germ cell interactions and male contraceptive development. *Physiol Rev.* 2002;82(4):825–874.
- Matter K, Balda MS. Signalling to and from tight junctions. *Nat Rev* Mol Cell Biol. 2003;4(3):225–236.
- Balda MS, Matter K. Epithelial cell adhesion and the regulation of gene expression. *Trends Cell Biol*. 2003;13(6):310–318.
- Bazzoni G, Dejana E. Endothelial cell-to-cell junctions: molecular organization and role in vascular homeostasis. *Physiol Rev.* 2004;84(3): 869–901.
- Furuse M, Tsukita S. Claudins in occluding junctions of humans and flies. *Trends Cell Biol*. 2006;16(4):181–188.
- 24. Linder S. The matrix corroded: podosomes and invadopodia in extracellular matrix degradation. *Trends Cell Biol.* 2007;17(3): 107–117.
- Chhabra ES, Higgs HN. The many faces of actin: matching assembly factors with cellular structures. *Nat Cell Biol*. 2007;9(10):1110–1121.
- McEver RP, Zhu C. Rolling cell adhesion. Annu Rev Cell Dev Biol. 2010;26:363–396.
- Parsons JT, Horwitz AR, Schwartz MA. Cell adhesion: integrating cytoskeletal dynamics and cellular tension. *Nat Rev Mol Cell Biol*. 2010; 11(9):633–643.

- Mullins RF, Skeie JM, Folk JC, et al. Evaluation of variants in the selectin genes in age-related macular degeneration. *BMC Med Genet*. 2011;12:58.
- Ciriza J, Garcia-Ojeda ME. Expression of migration-related genes is progressively upregulated in murine lineage-Sca-1+c-Kit+ population from the fetal to adult stages of development. *Stem Cell Res Ther.* 2010; 1(2):14.
- Kaartinen V, Voncken JW, Shuler C, et al. Abnormal lung development and cleft palate in mice lacking TGF-beta 3 indicates defects of epithelial-mesenchymal interaction. *Nat Genet.* 1995;11(4):415–421.
- Timmerman LA, Grego-Bessa J, Raya A, et al. Notch promotes epithelial-mesenchymal transition during cardiac development and oncogenic transformation. *Genes Dev.* 2004;18(1):99–115.
- Moreno-Bueno G, Cubillo E, Sarrió D, et al. Genetic profiling of epithelial cells expressing E-cadherin repressors reveals a distinct role for snail, slug, and E47 factors in epithelial-mesenchymal transition. *Cancer Res.* 2006;66(19):9543–9556.
- Yang J, Weinberg RA. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. *Dev Cell*. 2008;14(6): 818–829.
- Hoffman AE, Zheng T, Ba Y, et al. Phenotypic effects of the circadian gene cryptochrome 2 on cancer-related pathways. *BMC Cancer*. 2010;10:110.
- Tetsu O, McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. *Nature*. 1999;398(6726):422–426.
- Fearon ER. PARsing the phrase "all in for axin" Wnt pathway targets in cancer. *Cancer Cell*. 2009;16(5):366–368.
- White BD, Chien AJ, Dawson DW. Dysregulation of Wnt/beta-catenin signaling in gastrointestinal cancers. *Gastroenterology*. 2012;142(2): 219–232.
- MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. *Dev Cell*. 2009;17(1):9–26.
- Di Cristofano A, Pandolfi PP. The multiple roles of PTEN in tumor suppression. *Cell*. 2000;100(4):387–390.
- Waite KA, Eng C. Protean PTEN: form and function. *Am J Hum Genet*. 2002;70(4):829–844.
- 41. Chalhoub N, Baker SJ. PTEN and the PI3-kinase pathway in cancer. *Annu Rev Pathol.* 2009;4:127–150.
- Wang H, Chen P, Liu XX, et al. Prognostic impact of gastrointestinal bleeding and expression of PTEN and Ki-67 on primary gastrointestinal stromal tumors. *World J Surg Oncol.* 2014;12:89.
- Tang H, Yao L, Tao X, et al. miR-9 functions as a tumor suppressor in ovarian serous carcinoma by targeting TLN1. *Int J Mol Med.* 2013; 32(2):381–388.
- Sakamoto S, McCann RO, Dhir R, Kyprianou N. Talin1 promotes tumor invasion and metastasis via focal adhesion signaling and anoikis resistance. *Cancer Res.* 2010;70(5):1885–1895.
- Sommers CL, Byers SW, Thompson EW, Torri JA, Gelmann EP. Differentiation state and invasiveness of human breast cancer cell lines. Breast Cancer Res Treat. 1994;31(2–3):325–335.
- Zhu H, Lu J, Wang X, et al. Upregulated ZO-1 correlates with favorable survival of gastrointestinal stromal tumor. *Med Oncol.* 2013;30(3): 631.
- Doi Y, Yashiro M, Yamada N, Amano R, Noda S, Hirakawa K. VEGF-A/ VEGFR-2 signaling plays an important role for the motility of pancreas cancer cells. *Ann Surg Oncol.* 2012;19(8):2733–2743.
- Walsh N, Clynes M, Crown J, O'Donovan N. Alterations in integrin expression modulates invasion of pancreatic cancer cells. *J Exp Clin Cancer Res.* 2009;28:140.
- Sena P, Mariani F, Marzona L, et al. Matrix metalloproteinases 15 and 19 are stromal regulators of colorectal cancer development from the early stages. *Int J Oncol.* 2012;41(1):260–266.
- 50. Wu Y, Zhou BP. Snail: more than EMT. Cell Adh Migr. 2010;4(2): 199–203.
- Fan F, Samuel S, Evans KW, et al. Overexpression of snail induces epithelial-mesenchymal transition and a cancer stem cell-like phenotype in human colorectal cancer cells. *Cancer Med.* 2012;1(1):5–16.

- Hotz B, Arndt M, Dullat S, Bhargava S, Buhr HJ, Hotz HG. Epithelial to mesenchymal transition: expression of the regulators snail, slug, and twist in pancreatic cancer. *Clin Cancer Res.* 2007;13(16):4769–4776.
- von Burstin J, Eser S, Paul MC, et al. E-cadherin regulates metastasis of pancreatic cancer in vivo and is suppressed by a SNAIL/HDAC1/HDAC2 repressor complex. *Gastroenterology*. 2009;137(1):e361–e365.
- Shin NR, Jeong EH, Choi CI, et al. Overexpression of snail is associated with lymph node metastasis and poor prognosis in patients with gastric cancer. *BMC Cancer*. 2012;12:521.
- Kuo KT, Chou TY, Hsu HS, Chen WL, Wang LS. Prognostic significance of NBS1 and snail expression in esophageal squamous cell carcinoma. *Ann Surg Oncol.* 2012;19(suppl 3):S549–S557.
- van Nes JG, de Kruijf EM, Putter H, et al. Co-expression of SNAIL and TWIST determines prognosis in estrogen receptor-positive early breast cancer patients. *Breast Cancer Res Treat*. 2012;133(1):49–59.
- Wu Y, Zhou BP. New insights of epithelial-mesenchymal transition in cancer metastasis. *Chin J Biochem Biophys.* 2008;40(7):643–650.
- Friess H, Yamanaka Y, Büchler M, et al. Enhanced expression of transforming growth factor beta isoforms in pancreatic cancer correlates with decreased survival. *Gastroenterology*. 1993;105(6):1846–1856.
- Rowland-Goldsmith MA, Maruyama H, Kusama T, Ralli S, Korc M. Soluble type II transforming growth factor-beta (TGF-beta) receptor inhibits TGF-beta signaling in COLO-357 pancreatic cancer cells in vitro and attenuates tumor formation. *Clin Cancer Res.* 2001;7(9): 2931–2940.
- 60. Melisi D, Ishiyama S, Sclabas GM, et al. LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. *Mol Cancer Ther.* 2008;7(4):829–840.
- Misra S, Sharma S, Agarwal A, et al. Cell cycle-dependent regulation of the bi-directional overlapping promoter of human BRCA2/ZAR2 genes in breast cancer cells. *Mol Cancer*. 2010;9:50.
- Lu H, Yue J, Meng X, Nickoloff JA, Shen Z. BCCIP regulates homologous recombination by distinct domains and suppresses spontaneous DNA damage. *Nucleic Acids Res.* 2007;35(21):7160–7170.
- Liu X, Cao L, Ni J, et al. Differential BCCIP gene expression in primary human ovarian cancer, renal cell carcinoma and colorectal cancer tissues. *Int J Oncol.* 2013;43(6):1925–1934.

- Huang YY, Dai L, Gaines D, et al. BCCIP suppresses tumor initiation but is required for tumor progression. *Cancer Res.* 2013;73(23): 7122–7133.
- Cui X, Yu L, Wang Y, et al. The relationship between cyclin G1 and survival in patients treated surgically for HCC. *Hepatogastroenterology*. 2013;60(121):153–159.
- Wen W, Ding J, Sun W, et al. Cyclin G1-mediated epithelial-mesenchymal transition via phosphoinositide 3-kinase/Akt signaling facilitates liver cancer progression. *Hepatology*. 2012;55(6):1787–1798.
- 67. Li J, Muscarella P, Joo SH, et al. Dissection of CDK4-binding and transactivation activities of p34(SEI-1) and comparison between functions of p34(SEI-1) and p16(INK4A). *Biochemistry*. 2005;44(40): 13246–13256.
- Tang DJ, Hu L, Xie D, et al. Oncogenic transformation by SEI-1 is associated with chromosomal instability. *Cancer Res.* 2005;65(15): 6504–6508.
- van Dekken H, Alers JC, Riegman PH, Rosenberg C, Tilanus HW, Vissers K. Molecular cytogenetic evaluation of gastric cardia adenocarcinoma and precursor lesions. *Am J Pathol.* 2001;158(6):1961–1967.
- Tang TC, Sham JS, Xie D, et al. Identification of a candidate oncogene SEI-1 within a minimal amplified region at 19q13.1 in ovarian cancer cell lines. *Cancer Res.* 2002;62(24):7157–7161.
- Hsu SI, Yang CM, Sim KG, Hentschel DM, O'Leary E, Bonventre JV. TRIP-Br: a novel family of PHD zinc finger- and bromodomaininteracting proteins that regulate the transcriptional activity of E2F-1/ DP-1. *EMBO J.* 2001;20(9):2273–2285.
- Sugimoto M, Nakamura T, Ohtani N, et al. Regulation of CDK4 activity by a novel CDK4-binding protein, p34(SEI-1). *Genes Dev.* 1999; 13(22):3027–3033.
- Hong SW, Kim CJ, Park WS, et al. p34SEI-1 inhibits apoptosis through the stabilization of the X-linked inhibitor of apoptosis protein: p34SEI-1 as a novel target for anti-breast cancer strategies. *Cancer Res.* 2009;69(3):741–746.

OncoTargets and Therapy

Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on

Submit your manuscript here: http://www.dovepress.com/oncotargets-and-therapy-journal

patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.